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Human immunodeficiency virus (HIV) infection is nowadays considered to be a 
chronic infection due to the increasing accessibility of antiretroviral treatment 
(ART). However, it is still a major health concern with an estimated 36.9 million 
people carrying the infection in 2017 (UNAIDS, 2018a). HIV is transmitted 
mainly through significant exposure to HIV-infected bodily fluids (blood, 
semen and pre-seminal fluid, vaginal and cervical secretions) and from mother 
to child during pregnancy, delivery, or breast feeding (referred to as vertical trans-
mission). Thus, the three main groups at risk of acquiring HIV infection are 
men having sex with men (MSM), people who inject drugs (PWID; formerly 
referred to as intravenous drug users [IDUs]), and commercial sex workers 
(CSW). Implementing different precautionary methods, e.g. testing of donor 
blood and various forms of needle/syringe programs, have helped to decrease 
the number of new HIV cases each year in most parts of the world. However, 
the HIV incidence rate is still increasing in some regions (www.who.int).  
As parenteral transmission of HIV carries the highest rate of transmission, 
PWID are considered to be one of the most vulnerable groups for HIV infection. 
They are estimated to be 22 times more likely to acquire HIV than the general 
population (UNAIDS, 2018a). Receptive sharing of needles and other injection 
equipment, which in some communities can be seen as a form of bonding 
(Thompson et al., 2011), fuels the ongoing HIV epidemic among PWID. 
However, among PWID there are a number of individuals who, despite being 
highly exposed, remain seronegative, making them a useful population for HIV 
susceptibility studies. With every infection, the acquisition of the infection 
depends on a variety of factors. In addition to the level of exposure, e.g. in the 
case of PWID the duration of intravenous drug use (IVDU) and injection 
frequency, an individual’s immunologic markers and genetics have an impact as 
well. However, in the case of PWID the IVDU itself (especially with the use of 
opioids) also affects the host’s immune system to a degree where the levels of 
immune activation and the distribution of immune cells differ from non-users 
(McCarthy et al., 2001; Vallejo et al., 2004). 
Aside from the immunologic and genetic markers and behavioural factors, 
coinfections also play an important role as they increase the overall burden on 
the patient’s immune system and thus may alter their susceptibility to HIV 
infection and overall disease progression (Goletti et al., 1996; Kallestrup et al., 
2005; Stein, 1995). The possible direct and indirect interactions between HIV and 
a coinfection (e.g. tuberculosis [TB], viral hepatitis) might affect susceptibility 
to HIV and the disease progression. The coinfections may occur because HIV 
and other viruses follow the same parenteral route of transmission (e.g. hepatitis 
B virus [HBV], hepatitis C virus [HCV]) or because the HIV infection damages 
the immune system and thus makes the host more prone to opportunistic 
infections (e.g. [recurrent] tuberculosis, herpesvirus infection). Coinfected 
individuals have a higher risk of failing treatment and experiencing onset of 
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symptoms, either HIV-related or coinfection-related, than monoinfected patients. 
Interestingly, some coinfections (e.g. human T-lymphotropic virus [HTLV] and 
human pegivirus [HPgV]) have been shown to have beneficial effects on HIV-
infected individuals, resulting in slower disease progression and decreased 
morbidity and mortality (Barrios et al., 2011; Beilke et al., 2007; Maidana-Giret 
et al., 2009; Schwarze-Zander et al., 2010).  
The most common coinfections among people living with HIV (PLWH) are 
tuberculosis and viral hepatitis. A majority of viral hepatitis cases globally are 
caused by HBV and HCV viruses (www.who.int). HBV and HCV are hepato-
tropic viruses mainly contracted through blood, but also transmissible via sexual 
contact and from mother to child. With both viruses the infection could become 
chronic and cause major health problems, e.g. liver cirrhosis, liver cancer, and 
even death. People coinfected with HIV and HBV or HCV experience a faster 
progression to liver disease or liver failure and higher liver-related mortality 
than patients with HBV or HCV infection alone. The epidemiology and the 
pathogenic characteristics of viral hepatitis and TB have been investigated in 
Estonia (Blöndal, 2007; Brjalin et al., 2012; Kiiver et al., 2006; Kuznetsova et 
al., 2013; Nathanson et al., 2006; Zusinaite et al., 2005). Two more recent 
theses focused on finding associations between genetic (chemokine receptor 5 
[CCR5] haplotypes and expressions of CCR5 natural ligands) and immunologic 
markers (immune activation and CCR5 expression levels) and HCV and/or HIV 
acquisition among PWID in Estonia (Huik et al., 2013b, 2013a, 2010; Kallas et 
al., 2016a, 2016b, 2015). However, no studies focusing on the epidemiology of 
these potentially beneficial coinfections or their associations with HIV infection 
have been conducted in the setting of the Eastern European HIV epidemic. 




2. REVIEW OF THE LITERATURE 
2.1. HIV epidemics in the world 
The estimated number of new human immunodeficiency virus (HIV) infections 
has slightly declined since 2010 and according to the World Health Organi-
sation’s (WHO) estimation 1.8 million (1.4–2.4 million) new HIV infections 
emerged in 2017 (www.who.int). By the end of 2017 the number of people 
living with HIV (PLWH) was approximately 36.9 million (31.1–43.9 million) 
(www.who.int). Although AIDS-related deaths have decreased by 45% since 
2005, the number of people dying from AIDS-related causes is still high – there 
were approximately 0.94 million (0.67–1.3 million) AIDS-related deaths in 
2017 (UNAIDS, 2018a). These decreases in HIV incidence and mortality rate 
are mainly due to increased accessibility of antiretroviral treatment (ART), a 
combination of drugs which directly inhibit various stages of the HIV life cycle. 
Although ART does not cure HIV, continued treatment suppresses viral 
replication which slows the progression of the disease and decreases the risk of 
transmission.  
Nearly two-thirds of PLWH live in Africa where the leading mode of trans-
mission is heterosexual intercourse followed by vertical transmission 
(www.who.int). Southern Africa has the highest HIV prevalence with the most 
vulnerable group being women aged 15–24 who are two times more likely than 
men to be living with HIV (UNAIDS, 2018a). In North America and Western 
Europe, sex between men has remained the predominant mode of HIV trans-
mission since the beginning of the epidemic (www.cdc.gov; ECDC and WHO 
Europe, 2018). In Eastern Europe many countries have experienced HIV out-
breaks among people who inject drugs (PWID). In recent years this PWID-driven 
Eastern European epidemic has been slowly transitioning into being mostly 
sexually driven. In 2017 the main mode of transmission in Eastern Europe was 
heterosexual intercourse (56%) followed by intravenous drug use (30%) (ECDC 
and WHO Europe, 2018). However, PWID still account for majority of PLWH 
in this region (www.euro.who.int).  
 
 
2.1.1. HIV epidemics in Eastern Europe 
The region of Eastern Europe and Central Asia is one of two regions in the 
world (the other being Middle East and North Africa) where the number of new 
HIV infections has continued to increase. By the end of 2017 the estimated 
number of PLWH in Eastern Europe and Central Asia was 1.4 million 
(1.3 million–1.6 million). The regional coverage of ART has somewhat 
increased in the last couple of years reaching 36% (29–41%) in 2017 (compared 
to 21% in 2015). However, the number of AIDS-related deaths has remained 
quite high at approximately 34,000 (25,000–41,000) in 2017. (UNAIDS, 2018a) 
12 
The introduction of HIV into Western and Central Europe took place in the 
early 1980s with a majority of infections being caused by subtype B and mainly 
among men having sex with men (MSM) (Brunet et al., 1984; Glauser and 
Francioli, 1984; Melbye et al., 1984; Robbins et al., 2003). During this time the 
number of HIV cases in Eastern Europe was small with a majority of infections 
being reported among MSM (Bobkova, 2013). However, in the mid-1990s a 
new type of HIV epidemic started in former Soviet Union (FSU) countries. 
Outbreaks of HIV in FSU countries had common characteristics: a majority of 
newly infected individuals were young males who had a history of intravenous 
drug use (IVDU). Ukraine was the first country to experience this Eastern 
European type HIV epidemic. In 1995 HIV outbreaks occurred among PWID in 
two Ukrainian cities, Odessa and Nikolayev, which were caused by HIV-1 
subtypes A and B, respectively (Kravchenko et al., 2002). In the following 
years many FSU countries reported HIV outbreaks among PWID (Balode et al., 
2004; Bobkov et al., 2001, 2004; Kurbanov et al., 2003; Lukashov et al., 1998; 
Zetterberg et al., 2004). A majority of these outbreaks were caused by the  
HIV-1 subtype A variant originating in Odessa (designated HIV-1 subtype AFSU) 
and this subtype has been predominant in the HIV epidemic in FSU countries, 
with some exceptions (Abecasis et al., 2013; Adojaan et al., 2005; Hemelaar et 
al., 2011; Liitsola et al., 1998; Masharsky et al., 2003).  
 
 
2.1.2. HIV epidemic in Estonia 
Although the first HIV-positive diagnosis in Estonia was made in 1988, the 
overall number of HIV-positive patients remained low (< 100 cases) (Ustina et 
al., 2001) until the second half of the year 2000, when the concentrated HIV 
epidemic broke out. It started as a typical Eastern European type epidemic 
where the majority of newly diagnosed HIV-positive patients were young males 
with a history of IVDU (Uusküla et al., 2002). The highest number of new HIV-
positive diagnoses, 105.3 per 100,000 inhabitants, was recorded in 2001. Since 
then, the number of new cases has been decreasing. Although HIV prevention 
has greatly improved in Estonia, the HIV incidence rate of 16.6 per 100,000 
inhabitants in 2017 is still one of the highest in Europe (www.terviseamet.ee; 
ECDC and WHO Europe, 2018). 
The main socioeconomic characteristics of the HIV outbreak in 2000 were 
different from those inherent to the spread of HIV in Estonia so far. In the 
1990s, HIV-1 was mainly transmitted through hetero- and homosexual contact 
and the prevailing genotype was HIV-1 subtype B. At the start of the epidemic, 
a vast majority of new HIV infections were diagnosed among PWID and nearly 
all HIV infections were caused by HIV-1 CRF06_cpx, a recombinant form 
consisting of fragments of HIV-1 subtypes A, G, K, and J (Montavon et al., 
1999). With the progression of the epidemic, a new unique recombinant form 
named CRF06A, consisting of fragments of HIV-1 CRF06_cpx and subtype A, 
started to spread along with the prevailing CRF06_cpx subtype (Adojaan et al., 
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2005). From 2009 the proportion of PWID among newly diagnosed HIV-
positive patients started to decrease which indicated that the epidemic was 
slowly moving into the general population. Today a little over half of newly 
diagnosed patients have self-reportedly acquired the infection through sexual 
contact (www.terviseamet.ee; Estonian HIV-positive Patients Database), but 
CRF06_cpx has remained to be the prevailing HIV-1 subtype in Estonia (Avi et 
al., 2014, 2011). 
 
 
2.2. Pathogenesis of HIV infection 
HIV viral genome is a single stranded positive-sense RNA which is packed into 
the viral particle (virion) in two copies. The main targets of HIV infection are 
activated CD4+ T cells. Through the attachment of the virion to the CD4 receptor 
and a coreceptor (mainly the C-C chemokine receptor 5 [CCR5] or C-X-C 
chemokine receptor 4 [CXCR4]), the virion’s core is released into the cytoplasm 
of the cell. Thereafter, the viral enzyme reverse transcriptase synthesizes double-
stranded DNA designated as HIV provirus using the viral genome as a matrix. 
The HIV proviral DNA is transported into the cell’s nucleus and integrated into 
the host’s genome.  
The primary infection results in a rapid decrease in CD4+ T cell count and 
peak HIV viremia in which the number of viral particles may reach several 
million per millilitre of blood (Figure 1) (Pantaleo et al., 1993). Thereafter, the 
HIV viral load decreases and the CD4+ T cell count increases to a setpoint 
which is largely established by adaptive and innate immune responses (Koup et 
al., 1994; Maartens et al., 2014). After the acute phase, a steady asymptomatic 
phase (also referred to as clinical latency) is achieved. For several years the 
changes in the levels of HIV viremia, CD4+ T cell count, and immune activation 
remain minimal. Throughout the infection, persistent immune activation and the 
cytopathic effects of HIV itself drive the depletion of CD4+ T cells (Lederman 
et al., 2000; Maartens et al., 2014). This, in turn, leads to a constant decrease of 
CD4+ T cells and increase of HIV viral load (VL). After a while, the patient 
will experience the onset of symptoms of opportunistic infections, and eventually 
AIDS and death. 
Today, the use of successful ART prolongs the clinical latency phase and the 
overall lifespan of all HIV-positive patients to the extent that the life expectancy 
is similar to that of HIV-negative individuals (Johnson et al., 2013; Nakagawa 
et al., 2013). However, in addition to controlling HIV with effective ART, the 
state of the patient’s immune system and their overall health depends on a 
variety of factors in which coinfections are one of the most important factors. 
They increase the overall burden on the patient’s immune system and may alter 
the risk of transmission and HIV disease progression (Chang et al., 2013).  
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Figure 1. HIV disease progression. The levels of CD4+ T cell count and HIV RNA 
are shown in black and red, respectively. With regards to coinfections, these might 
precede HIV, occur simultaneously with HIV (or after the primary infection) due to shared 
transmission routes, or arise due to the damage HIV has caused to the host’s immune 
system. Modified from Fauci and Pantaleo et al. (Fauci, 1988; Pantaleo et al., 1993). 
 
 
2.3. The route of transmission and HIV susceptibility 
HIV is transmissible via sexual exposure, from mother to child during pregnancy, 
labour or the postpartum period, and parenterally via transfusion of contami-
nated blood or blood products. Generally, the risk of infection via the sexual 
route is about 1 out of 1,000–2,000 exposures, but cofactors such as the type of 
sexual intercourse, stage of the HIV disease, presence of a coinfection (e.g. 
other sexually transmitted diseases), male circumcision, and genital ulcer disease 
greatly increase the risk of infection (Boily et al., 2009; Powers et al., 2008). 
The rate of vertical transmission during pregnancy, childbirth or breastfeeding 
is around 15%–45% and is affected by the maternal viral load, the stage of the 
HIV disease, the presence of coinfections, and obstetric and neonatal variables 
(Gumbo et al., 2010). The risk of infection is the highest via the parenteral route 
since there is no need for the viral particle to pass through physical and bio-
logical barriers. The transmission of HIV through contaminated blood products 
reaches as high as 90%–100% (Donegan et al., 1990; Msellati et al., 1990). 
However, the use of successful ART greatly decreases the viral load and thus 
the risk of transmission is much lower via all possible routes. With an 
 
15 
undetectable HIV VL, the risk of transmission is below one per cent from 
mother to child (www.who.int/hiv/pub/mtct/en/) and nearly absent through the 
sexual route (Rodger et al., 2016).  
 
 
2.3.1. People who inject drugs 
As parenteral transmission of HIV is the most effective, PWID are considered 
to be one of the most vulnerable groups to HIV infection. They are estimated to 
be 22 times more likely to acquire HIV compared to the general population 
(UNAIDS, 2018b). However, due to criminalisation and stigma, PWID are 
among those with least access to HIV prevention and treatment and healthcare 
in general (UNAIDS, 2016). Receptive sharing of needles and other injection 
equipment, which in some communities is seen as a form of bonding 
(Thompson et al., 2011), fuels the ongoing HIV epidemic among PWID. In 
addition, PWID are often more engaged in high-risk sexual behaviour such as 
unprotected sexual acts with their partners or trading sex for money or drugs 
(UNAIDS, 2018b). All of this has resulted in concentrated HIV outbreaks 
among PWID to transition into sexually driven epidemics – a phenomenon seen 
in many countries worldwide, including Estonia (Des Jarlais et al., 2012; Soodla 
et al., 2015).  
PWID populations often include a number of individuals who, despite being 
highly exposed, remain seronegative. This has made PWID and other highly 
exposed seronegative (HESN) individuals (e.g. HIV-discordant couples, children 
born to HIV+ mothers) a target of HIV susceptibility studies. In addition to the 
level of exposure, e.g. in the case of PWID, the duration of IVDU and injection 
frequency, an individual’s immunologic markers and genetics have an impact as 
well. However, with PWID, the IVDU itself (especially with the use of opioids) 
affects the host’s immune system to a degree where the levels of immune 
activation and the distribution of immune cells differ from non-users (McCarthy 
et al., 2001; Vallejo et al., 2004). Opioids exert immunomodulatory effects both 
directly, through binding to the opioid receptors on immune cells which leads to 
decreased phagocytosis and chemotaxis (McCarthy et al., 2001), and indirectly, 
through binding to the opioid receptors in the nervous system which leads to 
reduced macrophage phagocytosis, chemotaxis and cytokine production (Chao 
et al., 1990). Studies have demonstrated an upregulation of CCR5 and down-
regulation of β-chemokines in cell cultures and among drug users (Li et al., 
2002), which may lead to increased susceptibility to infections, including HIV. 
In addition, the distribution of immune cell subsets has been demonstrated to be 
different among exposed seronegative PWID vs PWID with reduced exposure 
or healthy volunteers (Kallas et al., 2016a; McCarthy et al., 2001; Vallejo et al., 
2004). All this taken together suggests that, in addition to consistent exposure to 
various blood-borne infections, intravenous drug use itself modulates the 
immune system and alters the immune response.  
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2.4. Host factors and HIV susceptibility 
Research has uncovered a variety of demographic, immunologic, and genetic 
factors which affect HIV acquisition and/or disease progression. Younger age 
and female gender have been associated with slightly higher CD4+ T cell count 
both before and after starting treatment, lower levels of HIV VL, slower disease 
progression, and lower risk of mortality (Bosch et al., 2007; Collazos et al., 
2007; Cuzin et al., 2007; García de la Hera et al., 2004; Jarrin et al., 2008). The 
immunological factors associated with altered susceptibility to HIV include 
specific antibodies, levels of β-chemokines (or CC-chemokines) and cytokines, 
chemokine receptor expressions, and distribution and effectiveness of immune 
cells. Although not all of the causes of these immunologic alterations are known, 
many of them have been shown to be due to changes in the human genetics, e.g. 
polymorphisms in chemokine receptor genes (Arenzana-Seisdedos and 
Parmentier, 2006; Gonzalez et al., 1999; Samson et al., 1996) and cytokine genes 
(Jiang et al., 2017; Shrestha et al., 2006; Wang et al., 2004), differences in 
chemokine allele frequencies (Gonzalez et al., 1999; Huik et al., 2010), and 
inheritance of killer inhibitory receptor family alleles (Tomescu et al., 2011).  
 
 
2.4.1. Genetic factors 
Research focusing on genes encoding HIV-1 coreceptors and their natural 
ligands, human leukocyte antigens (HLAs), and cytokines has demonstrated the 
effects of genetic factors on the acquisition of HIV (Table 1). The most widely 
studied genetic polymorphism is the 32 base pair deletion in the coding exon of 
the CCR5 gene designated as CCR5∆32 which creates a dysfunctional CCR5 
receptor (Samson et al., 1996). This results in CCR5∆32 homozygotes being 
highly resistant to HIV R5-tropic strains (Liu et al., 1996; Michael et al., 1997). 
The binding of β-chemokines induces internalization of the chemokine receptor, 
which abrogates binding to the HIV particle (Amara et al., 1997). Thus, the risk 
of HIV infection is lower with higher levels of β-chemokines. Although the 
reasons behind the fluctuations of β-chemokine levels are not fully understood, 
SNPs in the β-chemokine coding genes may affect their expression levels (Modi 




Table 1. Selection of genetic polymorphisms influencing HIV acquisition. 
Gene Polymorphism Effect on HIV References 
HIV coreceptors and their natural ligands 
CCR2 V64I Protective against HIV (Michael et al., 1997) 
CCR5 ∆32 Protective against HIV, 
slower progression 
(Dean et al., 1996) 
(Samson et al., 1996) 
 C101X Protective against HIV (Blanpain et al., 2000) 
CCL3 ss46566437 Protective against HIV (Modi et al., 2006) 
ss46566438 Protective against HIV (Modi et al., 2006) 
ss46566439 Protective against HIV (Modi et al., 2006) 
CCL3L1 ↑ copy number Protective against HIV, 
slower progression 
(Gonzalez et al., 2005)  
(Huik et al., 2010) 
CCL4L1 ↑ L2 allele ↑ susceptibility to HIV (Colobran et al., 2005) 
CCL5 −403A Protective against HIV, 
slower progression 
(Liu et al., 1996) 
(Zhao et al., 2004) 
MCP1/MCP3/
Eotaxin 
H7 haplotype Protective against HIV (Modi et al., 2006) 
HLA system 
HLA-A *02:01 ↑ susceptibility to HIV (Rallón et al., 2017) 
 *36 ↑ susceptibility to HIV  (Tang et al., 2008) 
HLA-C w*18 Protective against HIV (Lajoie et al., 2006) 
HLA-DQ B1*03:02 Protective against HIV (Rallón et al., 2017) 
HLA-E *0103 Protective against HIV (Lajoie et al., 2006) 
HLA-G +3142G ↑ susceptibility to HIV (Medeiros et al., 2018) 
 +3187A ↑ susceptibility to HIV (Medeiros et al., 2018) 
 *0105N Protective against HIV (Lajoie et al., 2006) 
Cytokines 
IL-2 166T Protective against HIV (Wang et al., 2004) 
 3896A Protective against HIV (Shrestha et al., 2006) 
IL-4 −590T Protective against HIV (Wang et al., 2004) 
(Wilson et al., 2001) 
 −589T Protective against HIV, 
slower progression 
(Nakayama et al., 
2002, 2000) 
IL-10 −592A ↑ susceptibility to HIV, 
faster progression 
(Jiang et al., 2017) 
 −1082G ↑ susceptibility to HIV, 
faster progression 
(Jiang et al., 2017) 




2.4.1.1. IFNL4 and HCV/HIV infection 
Interferons are a subfamily of cytokines which possess the ability to inhibit viral 
replication and protect the host cell from viral infection. Interferons are also 
engaged in the activation of other immune cells, such as NK cells and macro-
phages. Overall, there are three types of interferons. Type III interferons, known 
as interferon-lambdas (IFNλs), induce overlapping, signalling, and similar bio-
logical activities as IFNαs, including upregulation of major histocompatibility 
complex I antigen expression, induction of antiviral activity, and promotion of 
IFN-stimulated genes (Hong et al., 2016; Kotenko et al., 2003). The IFNλ 
family includes four distinct interferons (designated 1–4) located in chromo-
some 19 minus strand (Key et al., 2014). The most recently discovered IFNL4 
gene/pseudogene bears 30% amino acid identity with other IFNL genes 
(Prokunina-Olsson et al., 2013). Interestingly, the production of a functional 
IFNλ4 protein depends on the polymorphism located within the IFNL4 gene. 
The dinucleotide polymorphism rs368234815 located in the first exon creates a 
frame shift in the open reading frame which results in the loss of IFNλ4 protein 
production (Figure 2) (Prokunina-Olsson et al., 2013).  
 
 
Figure 2. Map of the IFNL4 gene. Purple boxes indicate exons and purple lines introns. 
The TT allele of the rs368234815 dinucleotide polymorphism creates a frameshift 
which results in loss of protein production. The ∆G allele of the rs368234815 
dinucleotide polymorphism creates a full-length IFNλ4 protein. Graphics modified from 
Key et al. (Key et al., 2014). 
 
In 2009, three separate study groups identified several genetic polymorphisms in 
interferon genes which were associated with spontaneous HCV clearance and 
improved interferon-based treatment response (Ge et al., 2009; Suppiah et al., 
2009; Tanaka et al., 2009). The single-nucleotide polymorphism designated 
rs12979860 located in the IFNL4 gene was demonstrated to have the strongest 
influence (Ge et al., 2009; Tanaka et al., 2009). The presence of the rs12979860 
C allele was associated with improved outcome with regards to treatment 
response and viral clearance (Ge et al., 2009; Salgado et al., 2011; Thomas et 
al., 2009). Carriers of the beneficial rs12979860 CC genotype showed a higher 
probability of achieving sustained virological response and higher rate of 
spontaneous viral clearance (Bruno et al., 2015; Daneshvar et al., 2016; Ge et 
al., 2009; Mangia et al., 2013; Sharafi et al., 2014). However, results on finding 
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associations between rs12979860 and susceptibility to or acquisition of HCV 
are controversial (Table 2).  
 
Table 2. Selection of studies investigating the association between rs12979860 and 
the acquisition of HCV or HIV 
Population Outcome Reference(s) 
Brazilian HCV+ patients 
and HCV− controls  
CC genotype protective against 
HCV acquisition  
(Bertol et al., 
2015) 
Iranian chronic HCV+  
and healthy controls 
No impact on HCV acquisition  
(Karkhane et 
al., 2016) 
Chinese chronic HCV+  
and healthy controls 
Combined CT/TT and rs10204525 
TT, ↑ risk of HCV infection 
(Xiao et al., 
2015b) 
Chinese chronic HCV+  
and healthy controls 
Combined CC and rs3087243 
GA/AA, ↑ risk of HCV infection 
(Xiao et al., 
2015a) 
Japanese chronic HCV+  
and healthy controls 
No impact on HCV acquisition 
(Ochi et al., 
2014) 
Egyptian chronic HCV+  
and healthy controls 
Presence of T allele,  
↑ risk of HCV infection 
(Pasha et al., 
2013) 
Chinese chronic HCV+  
and matched healthy controls 
C allele and CC genotype 
protective against HCV acquisition 
(Jin et al., 
2014) 
Moroccan HIV+,  
healthy volunteers of mixed 
Berber and Arabic ethnicity 
No impact on HIV acquisition, 
↑ CD4+ count in CC vs TT group 
after HAART initiation 
(Zaidane et al., 
2018) 
1 HIV+ of various ethnicities, 
HRSN of various ethnicities 
No impact on HIV acquisition 
or disease progression 
(Martin et al., 
2010) 
African American HIV+ natural 
suppressors, race matched 
controls of HIV+ with ↑ VL 
and HIV− 
No impact on HIV acquisition 
or natural viral suppression (Sajadi et al., 
2011) 
2 ESN individuals and  
their HIV+ partners 
Nonsignificant trend of ↑ CC 
prevalence among ESN vs HIV+ 
(Rallon et al., 
2011) 
Spanish HIV+ controllers  
and noncontrollers 




Meta-analysis of case-control 
studies (various ethnicities) 
Pooled analysis of 11/13 studies 
showed ↓ risk of HIV among 
CT/TT vs CC group 
(Tsiara et al., 
2018) 
Note. ESN – exposed seronegatives; HAART – highly active antiretroviral therapy; HCV – 
hepatitis C virus; HRSN – high-risk seronegatives; HIV – human immunodeficiency virus; VL – 
viral load. 1HRSN included both PWID and people with high-risk sexual behaviour;  
2ESN included HIV serodiscordant couples. 
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As HCV is a frequent coinfection among PLWH and the rs12979860 is located in 
an interferon-lambda coding gene which induces antiviral activity (Donnelly and 
Kotenko, 2010), some research groups have focused on determining whether the 
rs12979860 polymorphism has any effect on HIV (Table 2). So far the results 
have been controversial. Machmach et al. found the rs12979860 CC genotype to 
be associated with spontaneous HIV control – the CC genotype was more 
frequent among HIV controllers compared with non-controllers (Machmach et 
al., 2013). However, not all studies have detected similar associations between 
the INFL4 rs12979860 polymorphism and the acquisition or progression of HIV 
(Martin et al., 2010; Rallon et al., 2011; Salgado et al., 2011).  
 
 
2.5. HIV and coinfections 
HIV-associated coinfections can roughly be divided into two categories: 
infections which arise or occur more often due to the consistent damaging of the 
host’s immune system by HIV (opportunistic infections) and infections with 
similar transmission routes (mainly blood-borne viral infections).  
 
 
2.5.1. Opportunistic infections 
An impaired immune system enables these microorganisms, which are seldom 
part of the normal human microbiome, to increase their replication and establish 
infection. The weaker the immune system, the greater the impact opportunistic 
infections have on HIV-positive patients’ quality of life (www.cdc.gov/hiv; 
www.euro.who.int). Although a majority of these HIV-related opportunistic 
infections are becoming rarer with the constantly improving accessibility of 
ART, coinfections are still a major concern among PLWH.  
 
 
2.5.2. Coinfections with transmission routes similar to HIV 
As previously discussed, out of all the possible HIV transmission routes, trans-
mission via contaminated blood or blood products is the most effective route, 
reaching 90%–100% (Donegan et al., 1990; Msellati et al., 1990). Depending 
on the risk behaviour (duration and frequency of exposure), PWID populations 
are the most at risk for HIV acquisition. The most common coinfections among 
PWID, who account for the majority of HIV-infected people in Eastern Europe, 
are HBV and/or HCV infections (www.euro.who.int). 
Although HBV and HCV are taxonomically different with different genome 
organisations and replication cycles, they are both hepatotropic viruses which 
are mainly contracted through blood but are also transmissible via sexual 
contact and from mother to child. During the acute phase of HBV infection, 
most people do not experience any symptoms, but some develop rapid onset of 
illness with symptoms that last for several weeks, and a small subset of people 
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can develop acute liver failure, which can lead to death (www.who.int). The 
likelihood of chronic infection depends upon the age at which the infection was 
acquired, being the lowest in adults – less than 5% of people who acquired the 
infection as an adult will develop chronic infection. However, a vaccine against 
HBV is available and is 95% effective in preventing the infection. With HCV, 
the acute phase is usually asymptomatic and up to 20% of people may 
experience symptoms (www.who.int). About 15%–45% of infected persons 
spontaneously clear the virus without any treatment, others will develop chronic 
infection. At the moment, there is no vaccine against HCV but the direct-acting 
antiviral medications are effective with viral clearance being around 95% 
depending on the HCV genotype (Fathi et al., 2017; Sikavi et al., 2018). 
Both HBV and HCV are common among people living with HIV – an 
estimated 7.4% of HIV-infected individuals around the world are also infected 
with HBV and 6.2% of HIV-infected individuals show signs of past or present 
HCV infection (www.who.int). However, in the settings of concentrated HIV 
epidemics which have started among PWID, these numbers are significantly 
higher. Parental modes, e.g. IVDU or multiple transfusions are undoubtedly the 
most efficient routes of transmission for these viruses. In many cases, HIV 
epidemics among PWID is preceded by HBV and/or HCV infections (Burns et 
al., 1996; Lõhmus, 2009) which is likely due to HBV and HCV being more 
infectious and more easily contracted through blood-to-blood contact than HIV 
(Budd and Robertson, 2005). This has been the case in Estonia as well, where 
HIV epidemic first broke out among PWID (Figure 3). As a result, nearly half 
of HIV-positive patients in Estonia show signs of past or present HCV infection 
(Soodla et al., 2015) and the frequency is even higher among newly 
incarcerated prisoners and PWID (Kivimets et al., 2018; Uusküla et al., 2007).  
 
Figure 3. Incidence of HBV, HCV, and HIV in Estonia. Incidence per 100,000 
persons of HBV is marked in blue, HCV in green, and HIV in dark red. Graphics based 
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2.5.3. Impact of coinfections on HIV 
Most of the effects that coinfections have on HIV are caused by their influence 
on HIV VL. Studies have demonstrated that persistent or recurring coinfections 
such as malaria, herpes simplex virus type 2, helminths, and tuberculosis 
increase HIV VL (Barnabas et al., 2011; Modjarrad and Vermund, 2010). The 
increase in HIV VL increases the risk of transmission, which might further 
exaccerbate an epidemic. In most cases, clearing or supressing the coinfections 
also has a positive effect on HIV replication – significantly lowering HIV viral 
load after the treatment of coinfections means lowering the HIV transmission 
risk and slowing the HIV disease progression (Barnabas et al., 2011; Modjarrad 
and Vermund, 2010).  
In general, in vitro and in vivo studies indicate that coinfections could upregu-
late HIV transcription and activate cellular immunity, thus further burdening the 
host’s immune system and adversely influencing HIV transmission and disease 
progression (Goletti et al., 1996; Hoffman et al., 1999; Kallestrup et al., 2005; 
Stein, 1995; Walson et al., 2009). However, there are coinfections which have 
neutral or beneficial effects on the course of HIV disease progression such as 
Human T-lymphotropic virus (HTLV) and Human Pegivirus (HPgV) (Barrios et 
al., 2011; Beilke et al., 2007; Harrison et al., 1997; Maidana-Giret et al., 2009; 
Oo et al., 2015; Schwarze-Zander et al., 2010; Xiang et al., 2004). 
 
 
2.5.3.1 Human T lymphotropic virus 
Taxonomically HTLV belongs to the Primate T-lympotropic virus species, 
Deltaretrovirus genus, and Retroviridae family. Although there are four distin-
guished types, only HTLV-1 and HTLV-2 have spread globally causing lifelong 
infections in different regions around the world. Though the genome organi-
zation and transmission routes of HTLV-1 and HTLV-2 are similar (transfusion 
of contaminated blood, sexual contact, and from mother to child), they have 
different clinical outcomes (Proietti et al., 2005). HTLV-1 is the cause of adult 
T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical 
spastic paraparesis (HAM/TSP) in up to 5% of carriers (Proietti et al., 2005). So 
far, HTLV-2 is not definitively linked to any known human disease but has 
occasionally been associated with myelopathy and other neurological disorders 
(Araujo and Hall, 2004). HTLV-3 and HTLV-4 are recently discovered viruses 
from Central Africa which are both distinct from HTLV-1 and HTLV-2 (Wolfe 
et al., 2005). As only a few cases of individuals infected with HTLV-3 or HTLV-
4 have been documented, the pathogenicity of these viruses and associations with 






2.5.3.1.1. Prevalence of HTLV-1 and HTLV-2 
The number of HTLV-1-infected individuals is estimated to be between 5 and 
10 million globally (Gessain and Cassar, 2012). There are several major 
endemic regions of HTLV-1 infections. The highest prevalence of HTLV-1 
infection have been shown to be in Japan (up to 40% among adults over the age 
of 50 in some villages in southern Japan), Caribbean islands (up to 17% in 
Jamaica depending on age and sex; lower on other islands), South America 
(primarily Brazil with up to 1.8% among the general population in the city of 
Salvador de Bahia), Africa (primarily among Pygmy groups located in Central 
Africa with up to 10% depending on age), and among indigenous Australian 
population (up to 48% in Central Australia depending on sex and age) (Figure 4) 
(Einsiedel et al., 2016; Gessain and Cassar, 2012). In Western and Central 
Europe, the prevalence of HTLV-1 has been shown to be low, at around 0.005% 
among blood donors and 0.1% among pregnant women (ECDC, 2015; Taylor et 
al., 2005) and somewhat higher in countries with a higher presence of 
immigrants from HTLV-1-endemic regions (mainly France, the UK, Spain, and 
Portugal) (Nicolás et al., 2015). Data from Eastern Europe are largely missing 
except for Romania where the prevalence of HTLV-1 was shown to be slightly 
higher than in Western Europe (0.053% among blood donors) (Laperche et al., 
2009). 
Figure 4. Distribution of HTLV-1. HTLV-1-endemic regions are marked with red 
stars. Countries with high (1%–5%) HTLV-1 prevalence are marked with orange and 
countries with low (< 1%) HTLV-1 prevalence are marked with yellow. Graphics adapted 
from Gonçalves et al. (Gonçalves et al., 2010). 
 
Based on published reports, the distribution of HTLV-2 is geographically more 
restricted compared to the distribution of HTLV-1. It has primarily spread 
among different indigenous Amerindian (American Indian) populations in the 
Americas [up to 40% among tribes in the Amazonas region of Brazil (Ishak et 
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al., 1995), 8%–10% among tribes in Central America (Reeves et al., 1990; Vitek 
et al., 1995), up to 13% among tribes in North America (Gongora-Biachi et al., 
1997; Peters et al., 2000)], among Pygmy tribes in Central Africa (Goubau et al., 
1993; Vandamme et al., 1998), and among PWID in North America and Europe 
(Figure 5). The HTLV-2 prevalence in North America has been shown to be up 
to 20% among PWID living in metropolitan areas with the prevalence being 
higher among African-American PWID than Hispanic or white PWID (Briggs 
et al., 1995; Lee et al., 1990; Murphy et al., 1999). In Western and Central 
Europe, the prevalence of HTLV-2 has been shown to be up to 10% among 
PWID (de la Fuente et al., 2006; Giuliani et al., 2000; Henrard et al., 1995) and 
slightly higher among HIV+ PWID (14%) (Egan et al., 1999). The prevalence 
of HTLV-2 in Eastern European countries has not yet been studied.  
 
Figure 5. Distribution of HTLV-2. The prevalence of HTLV-2 is high among some 
tribes in North America, South America, and Africa (green dots) and people who inject 
drugs (red dots). Graphics adapted from Slattery et al. (Slattery et al., 1999). 
 
 
2.5.3.1.2. Impact of HTLV-1 on HIV infection 
HTLV-1 and HIV are structurally similar retroviruses which share transmission 
routes and thus, coinfections with these viruses are likely to exist (Klatzmann et 
al., 1984; Richardson et al., 1990). In vitro studies have demonstrated that the 
presence of HTLV-1 increases susceptibility to HIV (Kobayashi et al., 1990; 
Moriuchi et al., 1998). HTLV-1 induced higher production of tumour necrosis 
factor (TNF)-α in HTLV-1 infected cells and the production of soluble HTLV-1 
transcription activating protein (Tax1) have been shown to increase suscepti-
bility to HIV infection. More recent studies have largely focused on the 




Some reported no impact of HTVL-1 coinfection on HIV disease progression 
(Beilke et al., 2007; Harrison et al., 1997). Others have reported higher CD4+ T 
cell count, increased HIV replication, higher immune activation, and more 
advanced stages of HIV among HIV/HTLV-1 coinfected patients compared to 
those with HIV monoinfection (Beilke et al., 2004; Gudo et al., 2009; Sobesky 
et al., 2000) (Figure 6, A).  
 
 
Figure 6. Impact of HTLV-1 and HTLV-2 on coinfection with HIV. A) HTLV-1 and 
HIV coinfection. Although studies have shown higher CD4 T cell counts among patients 
coinfected with HTLV-1, patients show symptoms of more advanced HIV disease than 
HIV monoinfected individuals. B) HTLV-2 and HIV coinfection. HTLV-2 increases the 
expression of CC-chemokines and lowers the levels of CCR5 and immune activation 
markers. Overall, HTLV-2 coinfected persons experience slower HIV disease progres-
sion and lower mortality. Graphics based on previously published studies (Barrios et al., 
2011; Böhnlein et al., 1989; Leung and Nabel, 1988; Lewis et al., 2000; Oo et al., 2015; 
Schechter et al., 1994).  
 
 
2.5.3.1.3. Impact of HTLV-2 on HIV infection 
Another important T cell subpopulation in HIV infection is CD8+ T cells which 
are also the primary targets of HTLV-2 infection (Wang et al., 2000). In vivo 
studies have demonstrated that the transcriptional activating protein of HTLV-2 
(Tax2) increases the expression of CC-chemokines (CCL3, CCL4, CCL5) and 
downregulates the expression of CCR5 proteins on cell surfaces in HIV/HTLV-2 
coinfected CD4+, CD8+, and CD14+ cells compared to those infected with HIV 
alone (Barrios et al., 2011; Oo et al., 2015) (Figure 6, B). As the binding of CC-
chemokines induces the internalisation of the receptor which abrogates their 
binding to HIV particles (Amara et al., 1997), higher CC-chemokine levels and 
lower expression of CCR5 proteins would also inhibit the HIV-CCR5 binding 
and viral entry into cells, thus decreasing the risk of HIV acquisition and trans-
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mission. Indeed, studies have shown significantly lower levels of immune acti-
vation (expression of CD38), higher CD4+ T cell count, lower levels of HIV 
replication, and slower progression to AIDS and death among HIV/HTLV-2 
coinfected individuals than among HIV monoinfected individuals (Bassani et 
al., 2007; Beilke et al., 2004; Lewis et al., 2000). 
 
 
2.5.3.2. Human Pegivirus 
HPgV is a single-stranded positive sense RNA virus belonging to the Pegivirus 
C species, Pegivirus genus, and Flaviviridae family. It was discovered in 1995 
by two different study groups (Linnen et al., 1996; Simons et al., 1995). One of 
the groups referred to it as GB virus type C (GBV-C) after a surgeon with the 
initials G.B. from whose blood it was discovered and the other group Hepatitis 
G virus (HGV) since they thought it was one of the causative agents of human 
hepatitis. As the virus does not cause hepatitis and there is no proof the surgeon 
G.B. was infected with it (Alter, 1997; Alter et al., 1997; Stapleton, 2003; 
Theodore and Lemon, 1997), the names GBV-C and HGV are not accurate and 
it has been assigned to a new genus and renamed HPgV (Adams et al., 2013).  
The genome organisation and transmission routes (parenteral, from mother 
to child, sexual contact) of HPgV are similar to those of HCV (Simons et al., 
1995; Stapleton, 2003). Similar to HCV, HPgV does not replicate very well in 
vitro so conducting studies on the viral life cycle is challenging. Although 
HPgV RNA has been detected in a variety of different cell types (including 
hepatocytes), it is primarily a lymphotropic virus capable of replicating in 
primary T and B lymphocytes (George et al., 2006). The exact receptors for cell 
entry are unknown but it is thought that at least one of the receptors might be a 
low-density lipoprotein receptor (Chivero and Stapleton, 2015). Once inside the 
target cell, HPgV establishes an effective infection with mean plasma levels up 
to 5.6 × 108 genome equivalents per millilitre (George et al., 2003).  
HPgV viremia is usually cleared within the first years of infection in immuno-
competent individuals, but may persist for periods of time, especially among 
immunocompromised patients (Masuko et al., 1996; Thomas et al., 1998). This 
is at least partially due to HPgV envelope protein 2 (E2) incorporating a small 
peptide region capable of inhibiting TCR signalling and thus further inhibiting 
T cell activation and proliferation (Bhattarai et al., 2013). Additionally, unlike 
many other viral infections where viral genomic material and antibodies against 
viral components can be found simultaneously, it is not the case with HPgV 
infection. Antibodies against viral components (mainly E2) emerge with the 
clearance of HPgV viremia (Thomas et al., 1998). Patients who are simul-
taneously positive for HPgV RNA and anti-E2 antibodies are thought to be in a 
transitional state where the viremia is being eliminated. In addition, emerging 
antibodies appear to protect against reinfection with HPgV (Thomas et al., 
1998). However, the failure of producing antibodies against HPgV non-
structural proteins and the delayed production of anti-E2 antibodies suggest that 
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the active infection of HPgV might cause impairment in B cell function, which 
in turn helps the virus to persist (Chivero and Stapleton, 2015). 
 
 
2.5.3.2.1. Prevalence of HPgV 
HPgV infection is widely spread across the world. Still, among the general 
population the prevalence of HPgV viremia is quite low (1%–5%) in developed 
countries and significantly higher (up to 20%) in developing countries (Mohr 
and Stapleton, 2009; Reshetnyak et al., 2008). HPgV prevalence has been 
demonstrated to be higher among people with various underlying conditions (e.g. 
people infected with HIV) and people who are at risk of acquiring blood-borne 
infections (e.g. patients receiving haemodialysis, PWID) (Table 3). According to 
European and Russian reports, the frequency of HPgV viremia among HIV-
positive PWID in European region is up to 45% (Dmitriev et al., 2010; Rey et 
al., 1999; Wächtler et al., 2000).  
Based on the genomic sequences of the 5’ untranslated region (UTR), six 
different HPgV genotypes have been described so far. Although HPgV is globally 
distributed, certain genotypes are predominant in different geographic regions. 
The genotype distribution is consistent with ancient human migration patterns: 
genotype 1 is common in West Africa, genotype 2 (with distinguished subtypes 
2a and 2b) is common in North America and Europe, genotype 3 is common in 
Asia (Japan) (Muerhoff et al., 1997), genotype 4 is common in Southeast Asia 
(Myanmar and Vietnam), genotype 5 is common in South Africa, and genotype 6 
is common in Indonesia (Handajani et al., 2000; Naito et al., 1999; Reshetnyak et 
al., 2008; Tucker et al., 1999).  
 
Table 3. Prevalence of HPgV active infection (RNA positivity) among HIV+ patients 






3–57.5 (Dadmanesh et al., 2015; de Lamballerie et al., 1996; 
Grabarczyk et al., 2006; Jarvis et al., 1996; Masuko et 
al., 1996; Samarbaf-Zadeh et al., 2015) 
Drug users 18.9–34.5 (Anastassopoulou et al., 1998; Christensen et al., 2003; 
Kachko et al., 2005; Rey et al., 1999) 
HIV+ patients 17–88.8 (Anggorowati et al., 2013; Blackard et al., 2014; de 
Miranda et al., 2017; Dmitriev et al., 2010; Rey et al., 





2.5.3.2.2. Impact of HPgV on HIV infection 
HPgV is a frequent coinfection among HIV-positive patients (Dmitriev et al., 
2010; Rey et al., 1999; Wächtler et al., 2000), partly due to shared transmission 
routes but this might also be due to the impaired immune system of HIV-
positive patients, which may be less successful in clearing the virus. In vitro 
studies have shown HPgV to affect the HIV life cycle both directly, by inhibiting 
the steps of receptor binding and membrane fusion, and indirectly, by 
decreasing the expression of cell surface receptors CCR5 and CXCR4 and 
increasing the levels of their natural ligands CCL3, CCL4, CCL5, CXCL12 
(Jung et al., 2007; Maidana-Giret et al., 2009; Schwarze-Zander et al., 2010; 
Xiang et al., 2004), which might result in decreased susceptibility to HIV 
(Figure 7). Studies conducted among HIV-positive patients have shown indi-
viduals coinfected with HPgV to have improved immunological status (increased 
CD4+ T cell count, lower HIV viral load, lower expression of immune activation 
markers [CD69, CD86, and CCR5]) and delayed progression to AIDS, com-
pared to patients without HPgV coinfection (Bhattarai and Stapleton, 2012; 
Ernst et al., 2014; Heringlake et al., 1998; Lefrère et al., 1999; Schwarze-
Zander et al., 2012; Stapleton et al., 2013).  
 
 
 Figure 7. The impact of HPgV viremia on HIV infection. The direct and indirect 
effects HPgV infection has on the HIV life cycle at the cellular level results in beneficial 
effects at the host level. Compared to HIV monoinfected individuals, patients coinfected 
with HPgV have been shown to have higher CD T cell counts, decreased HIV VL and 
overall mortality, and delayed progression to AIDS. Graphics based on published 
reports (Bhattarai and Stapleton, 2012; Jung et al., 2007; Maidana-Giret et al., 2009; 





2. . Summary of the literature 
Parenteral modes, e.g. IVDU or multiple transfusions are undoubtedly the most 
efficient routes of HIV transmission. PWID are estimated to be the most at risk 
in acquiring HIV but due to criminalisation and stigma have the least access to 
HIV prevention and treatment. Therefore, they are considered to be one of the 
most vulnerable groups to HIV infection. However, PWID populations often 
include a number of individuals who, despite being highly exposed, remain 
seronegative which has made PWID a suitable target for HIV susceptibility 
studies. The acquisition of infections is affected by multiple factors, e.g. the 
level of exposure and an individual’s immunologic markers and genetics, but 
with PWID the injectable drug (especially opioids) also affects the host’s 
immune system so that the immune activation levels and the distribution of 
immune cells are different from non-users. Opioids exert immunomodulatory 
effects which result in decreased phagocytosis, chemotaxis, and cytokine produc-
tion and altered distribution of immune cell subsets (Chao et al., 1990; Kallas et 
al., 2016a; McCarthy et al., 2001), suggesting that in addition to consistent 
exposure the IVDU itself modulates the host’s immune responses. 
PWID and other highly exposed seronegative individuals (e.g. HIV discordant 
couples, children born to HIV+ mothers) have been the focus of studies investi-
gating the factors that influence susceptibility to HIV. Research focusing on 
genes encoding HIV-1 coreceptors and their natural ligands, human leukocyte 
antigens (HLAs), and cytokines has discovered multiple genetic factors which 
affect HIV acquisition. Several polymorphisms in interferon genes, a subfamily 
of cytokines with the ability to inhibit viral replication and protect the host cell 
from viral infection (Hong et al., 2016; Kotenko et al., 2003), have been dis-
covered to influence HCV acquisition, spontaneous clearance, and interferon-
based treatment response. The single-nucleotide polymorphism in the INFL4 
gene designated rs12979860 was demonstrated to have the strongest influence 
(Ge et al., 2009; Tanaka et al., 2009). As HCV is a frequent coinfection among 
PLWH, some research groups have focused on determining whether the 
rs12979860 polymorphism has any effect on HIV. However, so far the results 
have been controversial (Machmach et al., 2013; Martin et al., 2010; Rallon et 
al., 2011; Salgado et al., 2011). 
Most of the effects that coinfections have on HIV are a result of their influence 
on HIV VL. In general, coinfections may upregulate the transcription of HIV 
proviral DNA and activate cellular immunity, thus further burdening the host’s 
immune system and adversely influencing HIV transmission and disease 
progression (Goletti et al., 1996; Hoffman et al., 1999; Kallestrup et al., 2005; 
Stein, 1995; Walson et al., 2009). However, there are coinfections which exert 
neutral or beneficial effects on HIV such as HTLV and HPgV (Barrios et al., 
2011; Beilke et al., 2007; Oo et al., 2015; Schwarze-Zander et al., 2010). In vitro 
studies have demonstrated that the presence of HTLV-1 increases susceptibility 
to HIV (Kobayashi et al., 1990; Moriuchi et al., 1998). Population studies have 
been controversial with some reporting no effect of HTLV-1 on HIV and others 
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demonstrating higher CD4+ T cell counts, but also increased HIV replication, 
higher immune activation, and more advanced stages of HIV among 
HIV/HTLV-1 coinfected patients compared to HIV monoinfected individuals 
(Beilke et al., 2007, 2004; Gudo et al., 2009; Sobesky et al., 2000). With regards 
to HTLV-2, studies have shown increased expression of CC-chemokines 
(CCL3, CCL4, and CCL5) and downregulation of CCR5 expression on cell sur-
faces in HIV/HTLV-2 coinfected CD4+, CD8+, and CD14+ cells compared to 
those infected with HIV alone (Barrios et al., 2011; Oo et al., 2015). As the 
binding of CC-chemokines induces internalization of the receptor (Amara et al., 
1997) which abrogates their binding to HIV particles, higher CC-chemokine 
levels and lower expression of CCR5 proteins should also inhibit the HIV-CCR5 
binding and viral entry to the cell thus decreasing the risk of HIV acquisition 
and transmission. HPgV is a frequent coinfection among HIV-positive patients 
(Dmitriev et al., 2010; Rey et al., 1999; Wächtler et al., 2000), partly due to 
shared transmission routes but also possibly due to the impaired immune system 
of HIV-positive patients which may be less successful in clearing the virus. 
HPgV has been shown to inhibit the steps of HIV receptor binding and membrane 
fusion, decrease the expression of HIV coreceptors (CCR5 and CXCR4), and 
increase the levels of β-chemokines (Jung et al., 2007; Maidana-Giret et al., 
2009; Schwarze-Zander et al., 2010; Xiang et al., 2004), which potentially 
reduces susceptibility to HIV.  
As described above, polymorphisms in interferon genes impact HCV infection 
and, as interferons engage in antiviral activity, these polymorphisms could also 
affect HIV infection. In addition to genetic factors, coinfections influence HIV 
acquisition and disease progression too, especially coinfections with beneficial 
effects on the HIV infection. Thus, we have aimed to explore these areas further 





3. AIMS OF THIS STUDY 
The general aim of this study was to assess whether HIV coinfections and host 
genetics affect susceptibility to HIV infection in a Caucasian PWID population. 
The thesis focuses on two blood-borne viral infections and a genetic poly-
morphism located in the interferon-lambda-4 (IFNL4) gene. The specific objec-
tives were as follows: 
1.  To determine the prevalence and prevailing genotypes of HTLV-1 and 
HTLV-2 among healthy volunteers and PWID in Estonia. 
2.  To evaluate the associations between HTLV-1/2 positivity and sociodemo-
graphic factors, coinfections, and duration of intravenous drug use. 
3.  To determine the prevalence and prevailing genotypes of HPgV among 
PWID and to compare it with respective rates among healthy volunteers in 
Estonia. 
4.  To evaluate associations between HPgV and sociodemographic factors, 
coinfections, and duration of intravenous drug use. 
5.  To evaluate associations between the rs12979860 polymorphism located in 





4. MATERIALS AND METHODS 
Altogether, the thesis includes three cross-sectional studies (HTLV, HPgV, and 
IFNL4 rs12979860 studies) which were conducted among PWID, healthy 
volunteers, and blood donors. 
 
  
4.1. Study design and population 
The PWID were recruited using the respondent driven sampling (RDS) method 
(Malekinejad et al., 2008) in a syringe exchange program in Tallinn in 2011 
(Table 4). The Institute of Family Medicine and Public Health at the University 
of Tartu and the Estonian National Institute for Health Development conducted 
the recruitment of PWID into the RDS study through a syringe exchange 
program in Tallinn over the period from November to December 2011 [a more 
detailed description of recruitment is discussed in the previously published 
report (Uusküla et al., 2017)]. The current thesis includes one RDS study which 
began with six seeds. Every seed recruited up to three individuals from their 
social network to participate in the study. Each of the new participants recruited 
up to three individuals from their social network, etc. All recruited PWID filled 
in a questionnaire including demographic information (nationality, gender, date 
of birth, risk behaviour, duration of IVDU) and donated blood. The duration of 
IVDU was defined as the time between the first use of intravenous drugs and 
the time of recruitment. The duration of IVDU and age were measured in full 
years.  
 




No of recruits 
(sampling period) 
Control group; 

















(September 2011 – 
January 2012) 
To determine the 
prevalence of HPgV 
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(September 2011 – 
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To determine the 
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To evaluate the 
associations between 
IFNL4 rs12979860 
and the acquisition of 
HIV and/or HCV 
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Healthy volunteers were recruited in Tartu over a period from September 2011 
to January 2012. The healthy volunteers group included in the HPgV study was 
recruited first using statistical consideration and sample size calculation to 
determine the number of recruits and the group was composed based on the 
gender and age distribution of Estonian general population between the ages of 
18 and 65 years. The healthy volunteers’ group included in the HTLV study com-
prised of all the recruits from the HPgV study plus all the available samples 
from recruited healthy volunteers maintaining a similar age and gender distri-
bution. All healthy volunteers donated blood and filled in a questionnaire 
including demographic information (gender, date of birth).  
The leftover blood from the donors was collected from blood donation 
centres in Tallinn and Ida-Viru County in 2010. No demographic data (gender, 
age) about the blood donors were available. 
 
 
4.2. Ethical consideration 
All study protocols were evaluated and approved by the Research Ethics 
Committee of the University of Tartu (Ethics Committee approvals 204/T-13 on 
8th of June 2011, 209/T-16 on 11th of December 2011, and 216/T-18 on 25th of 
June 2012). Informed written consent was obtained from all the study subjects 
and healthy volunteers. All blood donors agreed that their leftover blood would 
be used anonymously for scientific purposes.  
 
 
4.3. Blood sampling and processing 
Approximately 8 to 16 ml of blood was taken via venepuncture into EDTA tubes 
(BD Diagnostics, New Jersey, NJ, USA). Within 24 h of blood collection, the 
samples were transported to the Department of Microbiology, University of 
Tartu and centrifuged at 1692 g for 5 min. Plasma was extracted and divided 
into aliquots. Peripheral blood mononuclear cells (PBMC) were separated from 
the remaining cell fraction by Ficoll gradient and divided into aliquots. The 
blood donors’ samples were collected into EDTA tubes, stored at +4ºC, and sent 
to the laboratory as whole blood after confirming their negativity for HIV, 
HBV, and HCV. All PBMCs, plasma and whole blood samples were stored at 
−80ºC for further analysis.  
 
 
4.4. Determination of HIV, HBV, and HCV serostatus 
The Estonian Central HIV Reference Laboratory performed HIV testing using a 
fourth generation enzyme-linked immunoassay (Abbott IMx HIV-1/HIV-2 III 
Plus, Abbott Laboratories, Abbott Park, Illinois, USA) and confirmed the results 
by immunoblotting (INNO LIA HIV I/II Score Western blot, Microgen Bio-
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products Ltd, Surrey, UK). The National Institute for Health Development 
performed HCV and HBV testing using ETI-AB-HCVK-3 anti-HCV test 
(DiaSorin, Vercelli, Italy) for determining HCV seropositivity (HCV+) and ETI-
MAK-4 HBsAg (DiaSorin, Vercelli, Italy), ETIAB-COREK Plus (anti-HBc, 
DiaSorin, Vercelli, Italy), ETI-AB-AUK-3 (anti-HBs, DiaSorin, Vercelli, Italy) 
for HBV. HBV positivity (HBV+) was defined as the presence of HBsAg. Past 
infection (HBV seropositivity) was defined as anti-HBc positivity and HBsAg 
negativity. Persons who were only anti-HBs positive were considered to be 
vaccinated against HBV infection. Detection of HIV, HBV, and HCV serostatus 
among 495 blood donors was done by the blood donation centres.  
 
 
4.5. Detection of HTLV-1 and HTLV-2 DNA 
DNA was extracted from 50 µl of PBMC suspension (104–105 cells) using 
Invitrogen PureLink Pro 96 Genomic DNA kit (Life Technologies, California, 
USA) according to the manufacturer’s instructions.  
The HTLV-1 long terminal repeat (LTR) region was amplified in two over-
lapping fragments, one from 5’ LTR-gag region and the other from 3’ tax-LTR 
region, which were thereafter assembled (van Tienen et al., 2012). The first 
round PCR included 1xHotStart Buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 1 unit 
of 6:1 mixture of HotStart Taq and Pfu DNA polymerase (all from Thermo-
Fisher Scientific Waltham, MA, USA) and 0.5 µM of HTLV-1 outer primers 
(Table 5). The second round PCR was carried out in the same conditions using 
HTLV-1 inner primers. PCR programs for the amplification of the 5’ LTR-gag 
fragment consisted of 35 cycles of 95 °C 30 s, 54 °C 30 s, 72 °C 45 s for both 
rounds, and for the amplification of 3’ tax-LTR fragment 35 cycles of 95 °C 
30 s, 52 °C 30 s, 72 °C 45 s for both rounds. The HTLV-2 LTR was amplified 
in first round PCR using 1xHotStart Buffer, 2 mM MgCl2, 0.2 mM dNTP, 
1 unit of 6:1 mixture of HotStart Taq and Pfu DNA polymerase (all from 
ThermoFisher Scientific Waltham, MA, USA), and 0.2 µM of HTLV-2 outer 
primers (Table 5) (Morimoto et al., 2007). The second round PCR was carried 
out in the same conditions, except 0.5 µM of HTLV-2 inner primers. PCR 
programs consisted of 35 cycles of 95 °C 30 s, 60 °C 30 s, 72 °C 45 s, for the 
first round and 35 cycles of 95 °C 30 s, 55 °C 30 s, 72 °C 45 s for the second 
round. HTLV-1 and HTLV-2 proviral DNA was detected with gel electro-
phoresis. The PCR products were directly sequenced using the ABI Prism Big 
Dye 3.1 fluorescent terminator sequencing chemistry (Applied Biosystems, 
Foster City, CA) with the second round HTLV-1 and HTLV-2 PCR primers for 
the determination of HTLV-1 and HTLV-2 subtypes. 
DNA extracted from chronically infected cell lines, MT-4 and Gu (HTLV-
1+ and HTLV-2+, respectively) (Moens et al., 2009), served as positive controls 




Table 5. PCR primers and probes used in the studies 




forward, outer 5’-AACTAGCAGGAGTCTATAAAAGCG-3’ 
reverse, outer 5’-AAAGATTTGGCCCATTGCCTAG-3’ 
forward, inner 5’-ACAGTTCAGGAGGGGGCTC-3’ 




forward, outer 5’-ACTCACACGGCCTCATACAG-3’ 
reverse, outer 5’-ACGCAGTTCAGGAGGCAC-3’ 
forward, inner 5’-CTGTTTGAAGAATACACCAACATCC-3’ 
reverse, inner 5’-CTCAACCGGCGTGGATGG-3’ 
HTLV-2 
forward, outer 5’-CAGGGCGAGTCATCGACCCAAAAG-3’ 
reverse, outer 5’-GAAGACAATGCTCCTAGGGCGGGC-3’ 
forward, inner 5’-ACCGTCTCACACAAACAATCCC-3’ 
reverse, inner 5’-GCGGGCCTGCCTATAGCGATG-3’ 
HPgV 
forward, outer 5’-AGGTGGTGGATGGGTGAT-3’ 
reverse, outer 5’-TGCCACCCGCCCTCACCCGAA-3’ 
forward, inner 5’-TGGTAGGTCGTAAATCCCGGT-3’ 







Note. HTLV and HPgV studies amplified regions of HTLV and HPgV viral genomes, 
respectively. The IFNL4 rs12979860 study determined the rs12979860 polymorphism within the 
human IFNL4 gene. All PCR primers were purchased from TAG Copenhagen A/S (Copenhagen, 
Denmark). 
 
4.6. Detection of HPgV 
Antibodies against HPgV were detected using an HGV Ab ELISA kit (Atlas 
Link Technology Co., Ltd, Beijing, China) according to the manufacturer’s 
instruction. Each run included two positive and three negative controls and all 
borderline results were retested. The presence of antibodies against HPgV is 
hereinafter referred to as HPgV seropositivity.  
In order to detect HPgV viremia, RNA from 140 µl of plasma was extracted 
using a QIAamp Viral RNA Mini kit (Qiagen, Hilden, Germany) according to 
the manufacturer’s instructions. cDNA was synthesized at a final volume of 
20 µl including 1xRT reaction buffer, 1 mM dNTP, 8 U of reverse transcriptase 
MuLV, 8 U of RNase inhibitor Ribolock, 8 pmol of HPgV outer reverse primer 
(Table 5), and 9.6 µl of extracted RNA. For the execution of synthesis process, 
the solution was kept at 37°C for 90 minutes and at 95 °C for 5 minutes. 
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For the amplification of HPgV 5’ UTR, nested PCR was used (Giret et al., 
2011). The first round PCR included 1xHotStart Buffer, 1.5 mM MgCl2, 
0.2 mM dNTP, 2.58 U of 6:1 mixture of Taq and Pfu DNA polymerase (all 
from ThermoFisher Scientific Waltham, MA, USA), and 0.5 µM of HPgV outer 
primers (Table 5), and 5 µl of cDNA. The second round PCR was carried out in 
the same conditions using HPgV inner primers. PCR programs consisted of 40 
cycles of 94 °C 30 s, 50 °C 30 s, 72 °C 30 s for the first round, and 40 cycles of 
94 °C 30 s, 60 °C 30 s, 72 °C 30 s for the second round. The presence of HPgV 
RNA is hereinafter referred to as HPgV viremia.  
PCR positive samples were directly sequenced using the ABI Prism Big Dye 
3.1 fluorescent terminator sequencing chemistry (Applied Biosystems, Foster 
City, CA) with the second round PCR sense primer used to determine the HPgV 
genotypes. Alignments were conducted using MEGA 6 software and phylo-
genetic tree was constructed using the maximum likelihood method with the 
Tamura-Ney substitution model. Sequences of different HPgV genotypes were 
extracted from GenBank and used as references. 
 
 
4.7. Detection of IFNL4 rs12979860 polymorphism 
For the detection of IFNL4 rs12979860 polymorphism, genomic DNA was 
extracted using Pure-Link® Pro 96 Genomic DNA Purification Kit (Invitrogen, 
Carlsbad, CA, USA). The genotyping was done using allelic discrimination 
analysis with appropriate primers and probes (Table 5) and the ABI7900HT 
Sequence Detection System (Applied Biosystems). 
 
 
4.8. Statistical analysis 
Statistical analysis was performed by the program R version 2.15.2 (www.r-
project.org) and Stata 14 (StataCorp, 2015). For our studies, descriptive statistics 
including percentages and absolute (n) frequencies for categorical variables, and 
medians and interquartile ranges (IQR) for continuous variables were calcu-
lated. Either Fisher’s exact test or the Mann–Whitney–Wilcoxon test was used, 
as appropriate, to evaluate differences between groups. Logistic regression 
analysis was used and odds ratios with corresponding 95% confidence intervals 
(CI) were calculated to further assess the impact of different variables on HIV 
susceptibility. All the variables which were significant in the univariate analysis 
were included in the multivariate analysis. Multivariate logistic regression 
models were used to determine the independent effects of the hosts’ demographic 
factors and coinfections’ statuses. With the IFNL4 rs12979860 study, an 
interaction term was included in the model and marginal effects at represen-
tative values were calculated using predictions from this model. All p-values 
below 0.05 were considered to be significant. 
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5. RESULTS AND DISCUSSIONS 
5.1. Population characteristics  
The PWID population included 345 PWID and this population was used in all 
three studies. The included PWID were predominantly young males with a high 
prevalence of HIV seropositivity (HIV+) (50%) and HCV+ (89%) (Table 6). 
The median duration of IVDU was 11 years (interquartile range [IQR] 7–14); 
64% of PWID reported receptive needle sharing in the past and 18% reported 
receptive needle sharing at least once a month during the last six months. 
Nearly two-thirds of PWID (62%) were positive for past HBV infection and 5% 
for active HBV infection. Approximately half (49%) of the PWID were HIV+ 
and HCV+. The self-reported questionnaires used during the recruitment process 
revealed that 91 PWID had a history of taking ART and 77% of them (71/91) 
were on ART at the moment of the recruitment. However, no data regarding the 
regimens or the duration of the treatment were available.  
 
Table 6. Main characteristics of PWID and healthy volunteers 
 
PWID 






N = 118 
Gender, n (%)    
Male 272 (79%) 59 (43%) 53 (45%) 
Age (years), median (IQR) 30 (25–34) 38 (27–51) 37 (27–49) 
Duration of IVDU (years), median (IQR) 11 (7–14) NA NA 
Receptively shared needles, n (%)    
Ever ¤ 220 (64%) NA NA 
Frequently $ 61 (18%) NA NA 
HIV status, n (%)    
Seropositive 172 (50%) 0 0 
HCV status, n (%)    
Seropositive 306 (89%) 0 0 
HBV status, n (%)    
Active infection 18 (5%) 0 0 
Past infection 214 (62 %) 0 0 
Vaccinated  43 (12%) 39 (28%) 35 (30%) 
HIV and HCV dual infected 169 (49%) 0 0 
HIV, HCV, and HVB triple infected 140 (41%) 0 0 
Note. NA – not applicable. Healthy volunteers’ groups are fitted to Estonian general population 
based on gender and age (between the ages of 18 to 65 years). The HIV, HCV, and HBV triple 
infection status are based on HCV and HBV seropositivity. * Healthy volunteers’ group included 
in the HTLV prevalence study. # Healthy volunteers’ group included in the HPgV prevalence 
study. ¤ Reported receptive needle sharing in the past. $ Reported receptive needle sharing at least 
once a month during the last six months. 
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Based on previous reports from Estonia and Eastern Europe, the characteristics 
of our PWID population are representative of this region – mainly young males 
with high prevalences of HIV and HCV seropositivity and low rate of PWID 
receiving ART (Heimer et al., 2017; Uusküla et al., 2015, 2014, 2007). In com-
parison to Western Europe, self-reported risk behaviour is higher among PWID 
in Eastern Europe than in Western Europe: PWID in Eastern Europe are more 
likely to engage in unprotected sexual intercourse (70% of HIV+ and 82% of 
HIV− vs 47% of HIV+ and 58% of HIV−) and receptive needle sharing (33%–
44% vs 4%–16%) than PWID in Western Europe (Uusküla et al., 2014).  
The number of healthy volunteers varied slightly for the HTLV and HPgV 
prevalence studies (Table 6). The HTLV study included 138 healthy volunteers 
with a median age of 38 years and HBV vaccination rate of 28%. The HPgV 
study included 118 healthy volunteers with a median age of 37 years and HBV 
vaccination rate of 30%. All healthy volunteers were HIV, HBV and HCV 
negative.  
No demographic data (age, gender) about blood donors used as a control 
group in the IFNL4 rs12979860 study were available. However, all of the blood 
donors were confirmed to be negative for HIV, HBV, and HCV infections.  
 
 
5.2. HTLV-1/2 study 
All of the 138 healthy volunteers were negative for both HTLV-1 and HTLV-2 
(prevalence 0%; 95% CI = 0.0–2.6) (Table 7). None of the PWID were HTLV-1 
positive, but one of the PWID was found to be positive for HTLV-2 (prevalence 
0.3%; 95% CI = 0.1–1.6). Unfortunately, we were unable to sequence the HTLV-2 
positive sample and therefore could not determine the HTLV-2 subtype or 
exclude the possibility of false positivity. All the HTLV-1 and HTLV-2 positive 
control samples were sequenced successfully. Due to the lack of HTLV-1 and 
very low prevalence of HTLV-2 found in our study group we were unable to 
evaluate any associations between HTLV-1/2 and risk factors.  
In accordance with our results, the prevalence of HTLV-1 and HTLV-2 has 
been shown to be low in the European region (< 0.1% in pregnant women; 
< 0.005% in blood donors) (ECDC, 2015; Laperche et al., 2009; Taylor et al., 
2005) and slightly higher in Romania (HTLV-1 prevalence 0.053% in blood 
donors) (Laperche et al., 2009) and European countries (the UK, France, Spain, 
Portugal) with high immigration from HTLV-1 endemic regions (Ireland et al., 
2017; Nicolás et al., 2015). The geographical distribution of HTLV-2 is some-
what different from HTLV-1 and in the European region HTLV-2 is mainly 
detected among PWID (Roucoux and Murphy, 2004). During the 1990s and 
early 2000s the frequency of HTLV-2 was around 10%–15% in Southern and 
Western European countries and around 3.4% in Sweden (de la Fuente et al., 
2006; Egan et al., 1999; Giuliani et al., 2000; Henrard et al., 1995). The rate of 
HTLV-2 infection seems to have decreased over time with more recent reports 
demonstrating significantly lower prevalence of HTLV-2 (around 1% or less) in 
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Southern and Western Europe (Hohn et al., 2017; Treviño et al., 2017) but the 
prevalence has remained roughly the same among PWID in Sweden (Malm et 
al., 2012).  
 




N = 172 
HIV− 
PWID 
N = 173 
P PWID 





HTLV-1, n (%) 0 0 – 0 0 – 
HTLV-2, n (%) 0 1 (0.6%) 1 1 0 1 
HPgV RNA, n (%) 71 (41%) 43 (25%) 0.023 114 (33%) 7 (6%) < 0.001 
HPgV Ab, n (%) 3 (1.7%) 5 (2.9%) 0.725 8 (2.3%) 2 (1.7%) 1 
* The healthy volunteers group included 138 people for the HTLV prevalence study and 118 
people for the HPgV prevalence study. 
 
 
5.3. HPgV study 
The HPgV antibody testing gave clear results with all healthy volunteers and 
nearly all PWID with only one sample remaining uninterpretable. The sequencing 
of the PCR products was successful in all of the samples from healthy volun-
teers and 98% (112/114) of the samples from PWID. 
 
 
5.3.1. HPgV RNA and seropositivity 
Of the 118 healthy volunteers seven had HPgV viremia; two had antibodies 
against HPgV (Table 7), and none had both. Of PWID, one-third was HPgV 
viremic and approximately 2% were HPgV seropositive (Table 7). Only two of 
the PWID tested positive for both RNA and antibodies, and one was positive for 
RNA but the antibodies remained uninterpretable. Based on previous reports, 
the state of being both HPgV seropositive and HPgV viremic is relatively rare 
(Descamps et al., 2006; Dille et al., 1997; Tacke et al., 1997). Thomas et al. 
suggested that the clearance of HPgV active infection occurs with emerging 
antibodies and patients carrying both HPgV RNA and anti-HPgV antibodies are 
likely during the transitional state of clearing the virus (Thomas et al., 1998). 
Our study demonstrates similar results: based on the results of RNA and 
antibody testing three PWID included in this study might have been in the stage 
of clearing HPgV viremia.  
The HPgV seropositivity was similarly low among both PWID and healthy 
volunteers (2.3% and 1.7%, respectively) (Table 7) and we found no asso-
ciations between variables (age and gender for healthy volunteers; age, gender, 
coinfection statuses, and duration of IVDU for PWID) and HPgV seropositivity. 
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Conversely, previous reports have demonstrated significantly higher prevalence 
of HPgV seropositivity among populations at risk of blood-borne infections 
(Aster et al., 2005; Descamps et al., 2006; Schwarze-Zander et al., 2006). How-
ever, not all patients who eliminate HPgV viremia develop anti-E2 antibodies 
(Schwarze-Zander et al., 2006). This in turn might at least partially explain the 
relatively low HPgV seropositivity.  
The HPgV viremia was significantly more frequent among PWID compared 
to healthy volunteers (33% and 6%, respectively) (Table 7). We found no asso-
ciations between gender or age and HPgV viremia among healthy volunteers, 
which might have been due to the low prevalence of HPgV viremia among them. 
However, we saw that HPgV viremic PWID were more likely younger and HIV 
positive compared to HPgV RNA negative PWID. Logistic regression analysis 
revealed that the HIV+ PWID had approximately two times increased odds of 
being HPgV viremic compared to HIV− PWID and the odds of being HPgV 
viremic decreased with increasing age (Table 8).  
Indeed, HPgV active infection has been shown to be more frequent in 
younger patients in a variety of different disease settings (e.g. HIV-infected, 
acute and chronic HCV-infected and HBV-infected, liver cirrhosis patients) 
(Dmitriev et al., 2010; Guilera et al., 1998; Rey et al., 2000; Wächtler et al., 
2000), groups at risk for blood-borne infections (e.g. PWID) (Anastassopoulou 
et al., 1998; Rey et al., 2000), and blood donors (Christensen et al., 2003). 
Healthy immunocompetent individuals tend to clear the HPgV viremia within 
the first couple of years (Masuko et al., 1996; Thomas et al., 1998), which 
might explain the association between RNA positivity and younger age. In the 
current study, we also investigated the possible associations between HPgV and 
HCV or HBV infections but did not find any which might have been due to high 
prevalence of HCV and HBV seropositivity in our study population. In the 
context of HIV/HCV dual infection (comparison of HIV−HCV−, HIV+HCV−, 
HIV−HCV+, and HIV+HCV+ groups) we found the prevalence of HPgV to be 
significantly higher in the HIV+HCV+ group than the HIV−HCV+ group 
(Paper II, Figure 2), which probably reflects the association between HPgV 
viremia and HIV infection. No associations were found between HPgV and 













Table 8. Associations from Univariate and Multivariate Logistic Regression Analyses 
of Variables and Human Pegivirus (HPgV) Infection among People Who Inject Drugs 
  Univariate Multivariate 
  Outcome Outcome 
  HPgV RNA+ HPgV RNA+ 
  OR (95% CI) P OR (95% CI) P 
Gender   NA  
 Male 1.0    
 Female 0.84 (0.48–1.48) > 0.05   
Age, years * 0.94 (0.90–0.98) 0.001 0.93 (0.90–0.97) 0.001 
Duration of IVDU, years * 0.97 (0.93–1.01) > 0.05 NA  
HCV status   NA  
 Negative# 1.0    
 Positive 1.29 (0.62–2.70) > 0.05   
HBV status   NA  
 Negative# 1.0    
 Positive 0.71 (0.21–2.43) > 0.05   
 Past infection 1.43 (0.80–2.58) > 0.05   
HIV status     
 Negative# 1.0  1.0  
 Positive 2.13 (1.34–3.36) 0.001 2.23 (1.39–3.58) 0.001 
HPgV serostatus   NA  
 Negative# 1.0    
 Positive 0.67 (0.13–3.36) > 0.05   
NA – not applicable. # Reference group. * Categorized as continuous variables, data reflects an 
increase in OR with each additional year of age or duration of intravenous drug use (IVDU). Only 
the variables which were significant in univariate analysis were included in multivariate analysis. 
 
 
5.3.2. Prevailing HPgV genotypes 
Based on the genotyping of HPgV 5’-UTR, only 2a and 2b genotypes were 
detected. This is consistent with previous reports demonstrating HPgV genotype 
2 to be prevailing in the European region with the vast majority of infections 
being caused by HPgV subtype 2a (Anastassopoulou et al., 1998; Björkman et 
al., 1998; Dmitriev et al., 2010; Neibecker et al., 2011; Valinciute et al., 2013). 
In the current study, six out of seven sequences from healthy volunteers 
belonged to HPgV genotype 2a and one to genotype 2b (Paper II, Figure 1). 
Among PWID, 79% (90/114) of the sequences belonged to HPgV genotype 2a 
and 19% (22/114) to genotype 2b. We constructed two separate phylogenetic 
trees (one for genotype 2a and one for genotype 2b) with additional reference 
sequences to further analyse the origins of HPgV viruses in Estonia. These trees 
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(Paper II, Supplementary Information) demonstrated that: a) a majority of the 
Estonian HPgV sequences are clustered together with different reference 
sequences indicating that HPgV infection has had multiple entries into the 
Estonian population; b) some sequences formed separate monophyletic clusters 
indicating that the use of injectable drugs and needle sharing might contribute to 
the rapid spread of HPgV infection among PWID. Although these identical 
clusters may suggest contamination, it is unlikely to be due to good laboratory 
practices and sample handling – all PCR runs included negative controls which 
were all clean; all sample collection and handling were done separately to 
minimize the risk of cross contamination; a majority of the sample identification 
numbers within these clusters are not adjacent which means the samples were 
analysed in different PCR runs. Indeed, identical or highly similar HPgV 
sequences have previously been found among high-risk groups like PWID and 
haemodialysis patients (Anastassopoulou et al., 1998; Masuko et al., 1996). We 
have seen similar monophyletic clusters with regards to the Estonian HIV 
CRF06_cpx sequence analyses as well (Avi et al., 2014) and studies which were 
sampled close to the year 2000 have even demonstrated the viral sequences to 
form one highly monophyletic HIV-1 CRF06_cpx cluster (Adojaan et al., 2005; 
Zetterberg et al., 2004). 
 
 
5.4. IFNL4 rs12979860 study 
Overall, IFNL4 rs12979860 genotyping was successful in 344/345 of PWID and 
in 495/497 of blood donors. The rs12979860 polymorphism was in Hardy–
Weinberg equilibrium in all groups.  
 
 
5.4.1. Distribution of rs12979860 genotypes 
The distribution of the IFNL4 rs12979860 genotypes among PWID and healthy 
volunteers was similar to what has been described in other study populations of 
European-American ancestry (Alestig et al., 2011; Indolfi et al., 2014; Kaczor et 
al., 2015; Nattermann et al., 2011; Sticchi et al., 2013). The distribution of 
rs12979860 genotypes differed between the HCV+ and HCV− PWID groups 
but did not reach statistical significance. In terms of HIV, the rs12979860 TT 
genotype was over-represented among HIV+ PWID compared to HIV− PWID 















N = 38 
HCV+ 
N = 306 
HIV− 
N = 172 
HIV+ 
N = 172 
Donors 
N = 497 
CC 19 (50%) 134 (44%) 78 (45%) 75 (44%) 225 (45%) 
CT 17 (45%) 132 (43%) 80 (47%) 69 (40%) 223 (45%) 
TT 2 (5%) 40 (13%) 14 (8%) 28 (16%) 47 (10%) 
Note. The HCV+ and HCV− groups are formed regardless of HIV serostatus. The HIV+ and 
HIV− groups are formed regardless of HCV serostatus. Bold indicates significant differences in 
the distribution of TT-genotype between study groups as follows: HIV+ vs HIV− p = 0.03 and 
HIV+ vs Donors p = 0.024. 
 
 
5.4.2. Associations between rs12979860 genotypes and HCV positivity 
We found no significant associations between the presence of rs12979860 
genotypes and the acquisition of HCV. Reports focusing on IFNL4 rs12979860 
polymorphism and susceptibility to HCV are somewhat controversial. In 
accordance with our results an Iranian study found no differences in the distri-
bution of rs12979860 genotypes between chronic HCV patients and healthy 
individuals (Karkhane et al., 2016). Others have found either the C allele or CC 
genotype to protect against HCV infection (Bertol et al., 2015) or the T allele to 
increase the odds of acquiring HCV infection (Pasha et al., 2013). However, as 
the HCV negative group included in our study was rather small, we acknow-
ledge that we might have had insufficient power to detect associations between 
rs12979860 polymorphism and the acquisition of HCV. Unfortunately, due to 
the hard-to-reach nature of PWID and the high infectivity of HCV via the 
parenteral route, it is difficult to recruit infection status-based study groups.  
 
 
5.4.3. Associations between rs12979860 genotypes and HIV positivity 
We found the rs12979860 TT genotype to be significantly more prevalent among 
HIV+ PWID compared to HIV− PWID. The few previous reports investigating 
the impact of rs12979860 genotypes on HIV acquisition have not found any 
associations (Martin et al., 2010; Rallon et al., 2011). Some studies have 
focused on determining the impact of rs12979860 genotypes on HIV prog-
ression. While Sajadi et al. found no associations between rs12979860 geno-
types and HIV VL (Sajadi et al., 2011), Machmach et al. found the rs12979860 
CC genotype to be associated with spontaneous HIV control (Machmach et al., 
2013). In addition, another study demonstrated significantly improved CD4+ T 
cell recovery after the initiation of ART among carriers of CC genotype 
compared to non-CC genotypes (Srinidhi et al., 2017). In the current study, we 
found an over-representation of the rs12979860 TT genotype among HIV+ 
44 
PWID and logistic regression analysis revealed that the presence of the TT 
genotype increased approximately two times the odds of being HIV positive 
(Table 10, Analysis A) compared to PWID with non-TT genotypes. In order to 
understand if and how the duration of IVDU influences the association between 
the acquisition of HIV and IFNL4 rs12979860 TT genotype we included the 
interaction between the TT genotype and the duration of IVDU in the model 
(Table 10, Analysis B). We observed a correlation between IFNL4 rs12979860 
and the duration of IVDU which was that the influence of the rs12979860 TT 
genotype on the acquisition of HIV decreased with increasing duration of 
IVDU. The analysis indicated that the presence of TT genotype increased the 
odds of being HIV positive more for people who had injected drugs for shorter 
periods of time. The odds ratio was largest with the duration of IVDU being less 
than one year (OR = 13.16, 95% CI = 2.16–80.21, p = 0.005) and it decreased 
1.16 times with every additional year of intravenous drug use (OR = 0.86, 95% 
CI = 0.75–0.98, p = 0.024). This effect lasted until the duration of IVDU was 12 
years or less (Figure 8). IVDU and sharing of injecting equipment are known to 
greatly impact the acquisition of blood-borne infections, including HIV (Kozlov 
et al., 2016; Morineau et al., 2012). Recurrent and increased duration of 
exposure increases the risk of infection. In line with that, our results suggest that 
although the TT genotype has an adverse effect on the acquisition of HIV, the 
impact of intravenous drug use is greater and with longer duration of 
intravenous drug use, the scale of this polymorphism’s impact diminishes over 
time. 
 
Table 10. Associations by logistic regression analysis of IFNL4 rs12979860 with HIV 
infection and duration of intravenous drug use (IVDU) among people who inject 
drugs 
A) Univariate analysis  Outcome: HIV+  
 OR (95% CI) P 
rs12979860   
Non-TT genotype a 1.0  
TT genotype 2.19 (1.11–4.33) 0.002 
 
B) Interaction analysis  Outcome: HIV+  
 OR (95% CI) P 
rs12979860   
Non-TT genotype a 1.0  
TT genotype 13.16 (2.16–80.21) 0.005 
Duration of IVDU# 1.08 (1.03–1.13) 0.001 
rs12979860-TT*IVDU 0.86 (0.75–0.98) 0.024 
Note. a Reference group. # Categorized as a continuous variable, data reflects an increase in OR 
with each additional year of duration of IVDU. 
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Based on HIV and HCV serostatuses, we divided the study population into 
subgroups and evaluated the distribution of IFNL4 rs12979860 TT genotype 
between these groups. We found a non-significant trend of increasing TT 
genotype frequency within study groups: 3% among HIV−HCV− (N = 35), 9% 
among HIV−HCV+ (N = 137), 14% among HIV+HCV+ (N = 169), and 33% 
among HIV+HCV− (N = 3) (Paper III, Table 3). Since we did not find any 
associations between the IFNL4 rs12979860 polymorphism and the acquisition 
of HCV, the discovered trend is likely due to the influence of rs12979860 
polymorphism on the acquisition of HIV.  
 
 
Figure 8. Prognosis of the logistic regression model used in interaction analysis. The 
durations of IVDU are measured in full years. If the duration of IVDU was less than one 
year, it was referred to as 0. 
 
 
 5.4.4. Associations between IFNL4 rs12979860 and HPgV 
To analyse whether the IFNL4 rs12979860 polymorphism has any effect on the 
acquisition of HPgV, we first divided the study population into groups based on 
HPgV RNA positivity and then based on HPgV antibody positivity (Table 11). 
With regards to associations between IFNL4 rs12979860 genotypes and HPgV 
RNA positivity or HPgV seropositivity, we found no significant differences. Our 
results suggest that the rs12979860 polymorphism does not affect the acqui-
sition of HPgV but, similar to HCV infection, the rs12979860 might affect the 
clearance of HPgV viremia. This is supported by the two PWID with RNA and 
antibody positivity and the one PWID with RNA positivity but uninterpretable 
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antibody testing as all three were the carriers of the rs12979860 CC genotype. 
However, due to a very low number of HPgV seropositive individuals and the 
cross-sectional study design, we were unable to draw any final conclusions on 
the associations between IFNL4 rs12979860 and HPgV clearance.  
 
Table 11. Distribution of IFNL4 rs12979860 genotypes among PWID groups based 




N = 113 
HPgV RNA− 
N = 231 
HPgV Ab+ 
N = 8 
HPgV Ab− 
N = 336 
CC 54 99 3 149 
CT 42 107 3 146 
TT 17 25 2 41 




6. GENERAL DISCUSSION 
Risk behaviours such as unprotected sexual contacts or using illegal substances 
and sharing of injection equipment among PWID drive the transmission of 
infectious diseases. As a result, the rates of HIV and HCV and/or HBV coinfec-
tions are shown to be extremely high among PWID in the Eastern European 
region (Nelson et al., 2011). As every infection burdens the host’s immune 
system, it may also alter their immune responses. In most cases, clearing or 
supressing the coinfections such as HCV or tuberculosis also has a positive 
effect on HIV. Sometimes the clearance of an infection is affected by the host’s 
genetics; for example, the CC genotype of the IFNL4 rs12979860 polymorphism 
greatly increases the odds of spontaneous clearance of HCV. However, some 
coinfections exert a neutral or beneficial effect on the course of HIV, e.g. HTLV 
and HPgV, and might even alter the susceptibility to HIV. The current study 
provides valuable information regarding the prevalence of HTLV-1/2 and 
HPgV infections and the influence of IFNL4 rs12979860 polymorphism on the 
susceptibility to HIV among PWID in the setting of the Eastern European type 
HIV epidemic.  
 
 
6.1. Selection of the study population 
We selected PWID to be our study population because PWID have remained to 
be the largest and most vulnerable group affected by HIV infection in Estonia. 
Although in recent years the Estonian HIV epidemic has transitioned into being 
sexually driven, PWID still account for a majority of PLWH. In Estonia the use 
of intravenous drugs increased substantially in 1994 and tripled by the late 1990s 
(Uusküla et al., 2002). This was followed by an increase in rates of HCV and 
HBV infections in the late 1990s and early 2000s and the sudden increase of HIV 
infection among PWID in 2000 (Estonian Health Board, www.terviseamet.ee). 
The main characteristics of Estonia’s HIV epidemic were similar to those seen 
in other Eastern European countries: the vast majority of newly diagnosed 
individuals were young males who had a long history of IVDU. HIV spread 
quickly among this hard-to-reach population during the early years of the 
epidemic and HIV incidence reached a high peak of 105.3 per 100,000 inhabi-
tants in 2001. Although HIV incidence started to decline in subsequent years, 
Estonia continues to have one of the highest HIV incidence rates in Europe 
(ECDC and WHO Europe, 2018). 
As HIV is mainly transmitted through sexual exposure globally, there is an 
abundance of research on groups at risk for HIV through sexual contact. 
However, PWID who mainly contract the virus parenterally are a less studied 
group. This is probably due to the stigma and criminalisation of drug use, 
resulting in the hidden nature of the PWID population which makes them more 
difficult to reach and monitor. The RDS method we used for the recruitment of 
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participants is an effective method for engagement with such a hard-to-reach 
population in research studies. In addition to HIV, PWID are at risk of acquiring 
other blood-borne infections. For example, HBV and HCV are widely spread 
among PWID worldwide (Nelson et al., 2011). As PWID exhibit higher risk 
behaviour, e.g. sharing of injecting equipment and unprotected sexual acts 
(Uusküla et al., 2014), they are a suitable target population for investigating the 
spread of blood-borne infections and making deductions about the possible 
transmission of these infections to the general population. The prevalence and 
prevailing genotypes of HTLV-1/2 and HPgV have never been studied in 
Estonia. Thus, these studies served as pilot studies to investigate whether HTLV-
1/2 and HPgV are rare or common among PWID and to decide if prospective 
studies regarding these viruses and their influence on HIV would be needed or 
feasible. Conducting these studies among PWID also enabled us to study the 
possible influence these viruses have on each other. In addition, most of the 
HIV outbreaks among PWID consist of monophyletic viral population in general 
and in Estonia in particular (Adojaan et al., 2005; Avi et al., 2011; Kostaki et 
al., 2018) which is probably due to the lack of protection offered by the mucosal 
barrier and the fast spread of one viral strain in parenteral transmission. This 




6.2. Potential reasons for low HTLV-1/2 prevalence 
We found all the study subjects to be negative for HTLV-1 and a very low 
prevalence of HTLV-2 among PWID in Estonia indicating that although 
HTLV-2 is present in this population it has not spread widely. As Estonia is an 
HTLV-1/2 non-endemic country, low prevalence was somewhat expected. In 
addition, there are very few immigrants from HTLV-1/2 endemic regions living 
Estonia who could potentially contribute to the higher prevalence of HTLV-1/2. 
Although we detected HTLV-2 in our PWID population, it seems that the 
PWID population in Estonia is relatively closed. First, we have seen that newly 
diagnosed patients are ageing with the epidemic – the newly diagnosed HIV-
positive patients including PWID are older in recent years than during the early 
years of the epidemic (Soodla et al., 2015). Second, only minor changes in the 
subtype distribution have been detected during the epidemic and a majority of 
infections have continued to be caused by HIV-1 CRF06_cpx since the outbreak 
in 2000 (Adojaan et al., 2005; Avi et al., 2014) suggesting that other viruses are 
rarely introduced into Estonia’s PWID population. 
As discussed in the review of the literature (Section 2.5.3.1.1. Prevalence of 
HTLV-1 and HTLV-2), in the European region HTLV-2 has mostly been 
detected among PWID and, based on recent reports, the prevalence has been 
decreasing. This is probably due to the implementation of harm reduction services 
for PWID (e.g. needle and syringe exchange programs, information on safe 
use/sex, distribution of condoms to PWID and their non-injecting partners, 
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infectious diseases testing and counselling) (ECDC and EMCDDA, 2011; 
Wiessing et al., 2017) in a majority of European countries which have increased 
awareness about the transmission of infectious diseases and improved the 
accessibility of clean injection equipment. The implemented harm reduction 
services show similar success in Estonia as well – the number of new HIV-
positive diagnoses among PWID has decreased drastically compared to the 
early days of the HIV epidemic. As we showed that HTLV-1/2 is rare among 
Estonian PWID, the population with the highest risk of acquisition, there is 
currently no need for routine screening of blood donors for HTLV-1 and 
HTLV-2. However, as our PWID-driven HIV epidemic has transitioned into 
being sexually driven, the situation needs to be monitored, especially since 
HTLV-1 and HTLV-2 are also transmissible through sexual contact and from 
mother to child (Proietti et al., 2005). 
 
 
6.3. Differences of HPgV viremia in our study populations 
Both HPgV viremia and seropositivity were relatively low among healthy 
volunteers in the current study indicating that, at least in the general population, 
HPgV has not spread widely. It could also mean that the introduction of HPgV 
into Estonian communities might have happened relatively late and thus the 
number of individuals who have managed to clear the virus is low. This is 
supported by the low seroprevalence of HPgV among PWID as well. However, 
the HPgV viremia was rather common among PWID in our study which indi-
cates rapid spread of HPgV in this population. It could also suggest that PWID 
are unable to clear the virus due to HIV or other infections (e.g. HCV) as reported 
previously (Masuko et al., 1996; Thomas et al., 1998). The possible inability to 
clear HPgV viremia could also be due to the behavioural characteristics of 
PWID as the IVDU itself affects the host’s immune system to a degree that 
PWID have higher levels of immune activation and impaired immune cells’ 
functioning compared to non-injectors (Chao et al., 1990; Kallas et al., 2016a; 
McCarthy et al., 2001). Then again, the low seroprevalence detected in our 
study could also be due to characteristics inherent to HPgV infection. The 
clearance of HPgV viremia is not always followed by the appearance of anti-E2 
antibodies (Boodram et al., 2011; Stapleton et al., 2004) resulting in individuals 
who show no signs of past HPgV infection. In addition, Devereux et al. showed 
that 5% of HIV-negative and 29% of HIV-positive patients had detectable anti-
E2 antibodies in the early sample but detectable anti-E2 antibodies were lost in 
most recent samples (median time between these samples 10.7 years, range 2 
months to 17 years) (Devereux et al., 1998). Interestingly, the loss of anti-E2 
antibodies was higher among HIV+ individuals which might at least partially be 
due to the immunocompromising effects of HIV infection. Therefore, the 
detection of anti-E2 antibodies might not accurately indicate the level of exposure 
to HPgV. Considering the aforementioned, the actual number of individuals 
who have had the HPgV infection in the past is probably higher than the 
50 
prevalence measured by the detection of anti-E2 antibodies which could explain 
the low rates of HPgV seroprevalence detected in our study.  
 
 
6.4. IFNL4 rs12979860 relation to gene functionality 
The current study demonstrated increased susceptibility to HIV infection among 
the carriers of the unfavourable TT genotype. Interestingly, the scale of this 
polymorphism’s influence decreased with increasing duration of IVDU. In 
accordance, previous studies have demonstrated that IVDU itself, especially 
receptive sharing of needles or other injection equipment, is a major risk factor 
for the acquisition of blood-borne viral infections such as HIV and HCV (Des 
Jarlais et al., 2018; Kozlov et al., 2016; Morineau et al., 2012). This, together 
with the results of our interaction analysis, suggests that strong environmental 
factors such as IVDU might have greater impact on the acquisition of viral 
infections than some polymorphisms in the human genome and continuous risk 
behaviour could diminish the potential influence of genetic polymorphisms.  
The unfavourable effect of the IFNL4 rs12979860 TT genotype on the 
acquisition of HIV we have seen in our study might be due to another functional 
polymorphism located in the same gene. The rs12979860 is in strong linkage 
disequilibrium with a functional dinucleotide polymorphism named rs368234815. 
The rs368234815 ∆G allele, which creates a frameshift resulting in the produc-
tion of full-length IFNλ4 proteins, correlates with the rs12979860 T allele 
perfectly in Asians (r2 = 1.00), well in Europeans (r2 = 0.92), and moderately in 
Africans (r2 = 0.71) (Prokunina-Olsson et al., 2013). Indeed, the rs368234815 
TT/TT genotype, which corresponds to rs12979860 CC genotype, has been 
associated with innate resistance to HIV infection among highly exposed sero-
negatives and with delayed disease progression among HIV-positive individuals 
(Machmach et al., 2015; Real et al., 2015). Since the frameshift created by the 
rs368234815 ∆G allele results in the production of the IFNλ4 protein, it 
suggests that the IFNλ4 protein might interfere with functions of immune 
response which are engaged in antiviral activity.  
 
 
6.5. Limitations of the study 
The current study has some limitations which should be acknowledged. First, 
due to the cross-sectional study design and the absence of clinical data (HIV 
viral load, CD4 cell count, HCV RNA and viral load, etc.) we were unable to 
assess the effect of HPgV viremia and IFNL4 rs12979860 polymorphism on the 
course of HIV infection or whether the rs12979860 polymorphism affects 
spontaneous HCV viral clearance in our population. In addition, we were not 
able to study the dynamics between HPgV viremia and seropositivity. However, 
as the primary aims were to determine the prevalence of HPgV among PWID in 
Estonia and to evaluate whether the IFNL4 rs12979860 polymorphism and 
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HPgV infection affect the acquisition of HCV or HIV, we believe the study 
design was appropriate. Second, nearly all HIV+ PWID were also HCV+ and 
few cases (< 10% of patients) had HIV or HCV monoinfections. This is not 
surprising as the median duration of IVDU was rather long and circulation of 
both infections in PWID communities has been well described (Balayan et al., 
2019; Degenhardt et al., 2017). Therefore, we were unable to detect any possible 
associations between the acquisition of HCV and HPgV viremia or IFNL4 
rs12979860 polymorphism. Third, the number of healthy volunteers in the HTLV 
study could have been higher to more accurately evaluate the prevalence of 
HTLV-1/2 among the general population of Estonia. However, as the preva-
lence of HTLV-1/2 has never been evaluated in Estonia, our study served as a 
pilot study. Regardless of the limitations pointed out, we believe the results 
presented in this thesis adequately describe the prevalence of HPgV and HTLV-
1/2 infections among PWID in Estonia and the associations between coinfections/ 
host genetics and the susceptibility to HIV infection.  
 
 
6.6. Future research 
The current thesis revealed associations between HIV and HPgV infections and 
the influence of IFNL4 rs12979860 TT genotype on the acquisition of HIV 
among PWID. HPgV has been shown to be a beneficial coinfection among 
HIV-positive patients with coinfected patients having an increased CD4+ T cell 
count, lower HIV viral load, decreased immune activation, and delayed progres-
sion to AIDS compared to HIV-monoinfected patients (Bhattarai and Stapleton, 
2012; de Miranda et al., 2017; Schwarze-Zander et al., 2012). However, the 
effects of HPgV coinfection among HIV patients initiating ART and the impact 
ART might have on HPgV viremia have not been fully studied. Even with the 
beneficial effects of HPgV on HIV infection, HPgV still establishes an effective 
infection with high viral load (George et al., 2003), which probably affects the 
normal functioning of the immune system and could thus be one of the factors 
affecting treatment response and HIV viral suppression after ART initiation. 
In addition to HPgV and HTLV-1/2, other coinfections might also affect the 
acquisition of HIV and possibly the disease progression as well. Previous 
studies have demonstrated that HIV infection is adversely affected by several 
viral infections such as herpes simplex virus type 2, Epstein-Barr virus, and 
cytomegalovirus (Barnabas et al., 2011; Basso et al., 2018; Hunt et al., 2011). It 
would be interesting to see whether and how these viruses might affect HIV 
infection and response to treatment in the settings of modern-day ART. 
Although nowadays treatment guidelines recommend ART initiation to all HIV-
positive patients regardless of CD4+ cell count (EACS, 2018), not all patients 
experience fully supressed HIV VL after the initiation of ART. In many cases, 
detectable HIV VL during ART might be due to adherence issues but coinfec-
tions in active replication phases could also be an influencing factor. 
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Another human pegivirus (HPgV-2) or the human hepegivirus type 1 
(HHpgV-1) has been discovered in recent years (Cuestas, 2016; Kapoor et al., 
2015). So far, studies indicate limited or absence of pathogenicity of this virus 
(Kandathil et al., 2017; Wang et al., 2018). The prevalence of HPgV-2 seems to 
be extremely low in the general population and somewhat higher among HCV 
monoinfected and HIV/HCV coinfected individuals suggesting low transmissi-
bility of the virus (Berg et al., 2015; Bonsall et al., 2016; Kapoor et al., 2015). 
Thus, studies among parenterally exposed risk groups might reveal associations 
between HPgV-2 and HCV. It may also clarify whether the HPgV-2 infection 
occurs among HCV monoinfected and HIV/HCV coinfected individuals more 
often due to the damage these viruses have done to the host’s immune system or 
the possible dependence of HPgV-2 replication on HCV infection (Bonsall et 
al., 2016; Kandathil et al., 2017; Kapoor et al., 2015; Wang et al., 2018).  
With regards to IFNL4, studies have revealed other polymorphisms in the 
IFNL4 gene that have been associated with HCV and/or HIV outcomes (mainly 
rs8099917 and rs368234815) (Cariani et al., 2016; Ikezaki et al., 2016; Real et 
al., 2015). It would be interesting to look at how rs12979860 and other poly-
morphisms located in or near the IFNL4 gene affect the dynamics of HIV viral 
load and the rate of disease progression. In addition, IFNλs have been shown to 
induce antiviral activity and successfully inhibit HCV and HIV replication in 
vitro (Donnelly and Kotenko, 2010; Kotenko et al., 2003). However, the IFNλ4 
protein production was recently demonstrated to be suppressed by the host’s 
immune system during viral infection (Hong et al., 2016). It is possible that the 
haplotype analysis on the basis of the polymorphisms in the IFNL4 locus might 




1.  We found all healthy volunteers and nearly all PWID to be negative for 
HTLV-1 and HTLV-2 viruses, suggesting that these viruses are not 
spreading in the Estonian population and currently there is no need to test 
blood products for these viruses.  
2.  Due to very low HTLV-1 and HTLV-2 prevalence in the studied population, 
we were unable to analyse any possible associations between HTLV-1/2 
positivity and sociodemographic factors, coinfections, and duration of intra-
venous drug use.  
3.  We demonstrated a low prevalence of HPgV viremia among healthy volun-
teers while it was significantly higher among PWID, especially those who 
were HIV positive at the same time, suggesting that HPgV transmits 
extremely well through the parenteral route and might be associated with the 
transmission of HIV. At the same time, HPgV seropositivity was low among 
all study groups which is probably affected by the characteristics inherent to 
HPgV infection: clearance of HPgV viremia is not always followed by the 
production of antibodies and/or produced antibodies might be lost during 
longer periods of time. Low seropositivity among PWID might also suggest 
their inability to clear HPgV viremia due to the immunocompromising 
effects of HIV and other coinfections. Similar to other neighbouring countries, 
a majority of all viruses belonged to HPgV genotype 2a and the only other 
detected genotype was 2b.  
4.  HPgV viremia but not seropositivity was associated with age and HIV 
positivity so that HPgV RNA-positive PWID were more likely to be younger 
and approximately twice as likely to be HIV positive compared to HPgV 
RNA-negative PWID. This association with age supports the previously 
described phenomenon where the clearance of HPgV viremia is not always 
followed by the production of antibodies against HPgV. A similar pheno-
menon was not observed among healthy volunteers. 
5.  HIV seropositivity depended on IFNL4 rs12979860 polymorphism. More 
specifically, PWID with the rs12979860 TT genotype were more likely to be 
HIV positive compared to PWID with non-TT genotype. The interaction 
analysis showed that the influence of TT genotype on the acquisition of HIV 
decreased with increasing duration of IVDU. It suggests a complex inter-
action between genetic and environmental factors where the IFNL4 
rs12979860 affects the acquisition of HIV but the impact of IVDU is greater 
and continuing such high risk behaviour diminishes the impact of this 




8. SUMMARY IN ESTONIAN 
Kaasuvate infektsioonide ja inimese geneetilise faktori mõju HIV-iga 
nakatumisele süstivate narkomaanide hulgas 
Antiretroviirusravi (ART) kättesaadavus on viimastel aastatel oluliselt paranenud, 
mistõttu sarnaneb inimese immuunpuudulikkuse viiruse (HIV) infektsioon üha 
rohkem krooniliste haigustega. Siiski on HIV infektsioon laialt levinud tervise-
probleem, mis esines 2017. aastal ligikaudu 36,9 miljonil inimesel üle kogu 
maailma. HIV levib peamiselt kokkupuutel viirust sisaldavate kehavedelikega. 
Võimalikest ülekandeteedest levib viirus kõige efektiivsemalt saastunud vere 
või vereproduktidega kokkupuutel. Seetõttu peetakse üheks kõige haavatava-
maks grupiks süstivaid narkomaane (SN) – võrreldes tavapopulatsiooniga on 
SN-del ligi 22 korda suurem risk nakatuda HIV-iga (UNAIDS, 2018b). Samas 
on uuringutes leitud SN-de seas indiviide, kes vaatamata sagedatele kokku-
puudetele ei nakatu HIV-ga. Iga infektsiooni tekke määravad peremeesorganismi 
immunoloogilised ja geneetilised faktorid, mis mõjutavad peremeesorganismi 
võimet haigustekitajaga võidelda. Leitud on mitmeid HIV-iga nakatumist mõju-
tavad geneetilisi polümorfisme HIV-1 koretseptorit ja selle ligande ning inimese 
leukotsüütide antigeene ja tsütokiine kodeerivates geenides. Interferoon-lambda-4 
(IFNL4) geenis paiknevat ühenukleotiidset polümorfismi on seni seostatud 
spontaanse hepatiit C viirusest (HCV) vabanemise ning interferoon-põhise ravi 
edukusega. Kuna HCV on laialt levinud infektsioon HIV positiivsete seas, siis 
võib antud polümorfism mõjutada ka HIV-iga nakatumist, kuid uuringute tule-
mused on senini olnud vastuolulised.  
Inimese immuunsüsteemi võimekus sõltub ka efektiivse ART korral mitmetest 
erinevatest faktoritest. Lisaks eelmainitutele on olulised ka kaasuvad infekt-
sioonid, mis immuunsüsteemi koormust suurendadesvõivad mõjutada nii vastu-
võtlikkust HIV infektsioonile kui ka haiguse kulgu. Kaasuva infektsiooni ja 
HIV infektsiooni omavahelised interaktsioonid võivad nii otseselt kui ka kaudselt 
mõjutada mõlema infektsiooni kulgu. Kaasuvatesse infektsioonidesse nakatumist 
soodustavad sarnased ülekandeteed, nt parenteraalselt hästi levivate hepatiit B 
(HBV) ja HCV viirusinfektsioonide korral, ja HIV-i immuunsüsteemi nõrgestav 
mõju, mis suurendab inimese vastuvõtlikkust (nt tuberkuloos, herpesviiruste 
infektsioonid). Samas, mõned kaasuvad infektsioonid (nt inimese T-lümfotroopse 
viiruse [HTLV] ja inimese pegiviiruse [HPgV] poolt põhjustatud infektsioonid) 
parandavad HIV positiivsete inimeste prognoosi, aeglustades haiguse kulgu 
ning vähendadas suremust.  
HTLV on HIV-ga sarnaste levikuteedega retroviirus, mis samuti põhjustab 
eluaegset infektsiooni. Eristatakse nelja tüüpi viirust, millest HTLV tüüp 1 
(HTLV-1) ja tüüp 2 (HTLV-2) on levinud üle maailma ning ülejäänud kahte 
tüüpi on tuvastatud üksikutel juhtudel Aafrika regioonis. HTLV-1 põhjustab 
kuni 10% kandjatest T-rakulist leukeemiat/lümfoomi või HTLV-ga seotud 
müelopaatiat (Proietti et al., 2005). HTLV-2 infektsiooni on seostatud mitmete 
neuroloogiliste häiretega (Araujo and Hall, 2004). HTLV-1 on laialt levinud üle 
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maailma, seejuures endeemiliselt Jaapanis, Kariibi mere piirkonnas, Lõuna-
Ameerikas, Aafrikas ning Austraalia aborigeenide seas (Gessain and Cassar, 
2012). HTLV-2 levik on geograafiliselt piiratum, levides Põhja- ja Lõuna-
Ameerikas indiaanlaste seas, mõningate hõimude seas Aafrikas ning Põhja-
Ameerika ja Euroopa regioonis SN-de seas (Slattery et al., 1999). In vitro 
uuringud on näidanud, et HLTV-1-ga nakatunud rakud on HIV infektsioonile 
vastuvõtlikumad kui nakatumata rakud. Inimestel, kes on infitseeritud nii 
HTLV-1 kui ka HIV-iga, on oluliselt kõrgem CD4 rakkude hulk, kõrgem im-
muunaktivatsioon ja kaugem HIV haiguse staadium. HTLV-2 ja HIV kaksik-
infektsiooni puhul on täheldatud CC-kemokiinide kõrgemat taset ja CCR5 
madalamat taset, mis võiksid oluliselt vähendada rakkude vastuvõtlikkust HIV-
le ning aeglustada HIV infektsiooni kulgu.  
HPgV on 1995. aastal avastatud pegiviiruste perekonda ja flaviviiruste sugu-
konda kuuluv peamiselt lümfotsüüte nakatav viirus, mille genoom on positiivse 
polaarsusega üheahelaline RNA (Linnen et al., 1996; Simons et al., 1995). Kuigi 
HPgV levikuteed ja genoomi struktuur on sarnased HCV-le, ei põhjusta HPgV 
hepatiiti. HPgV on laialdaselt levinud – arenenud riikides on tavapopulat-
sioonist kuni 5% viiruse kandjad ning arengumaades on sama näitaja umbes 
20% (Mohr and Stapleton, 2009). Normaalselt toimiva immuunsüsteemiga isikute 
puhul toimub viirusest vabanemine esimese paari aasta jooksul. Haiguslike 
seisundite ja immuunpuudulikkuse (nt HIV infektsiooni) korral võib HPgV 
infektsioon krooniliseks muutuda. In vitro uuringud on näidanud, et HPgV 
inhibeerib HIV-i elutsüklit mitmeti, nt vähendades CCR5 ja CXCR4 retseptorite 
ekspressiooni ja suurendades nende naturaalsete ligandide ekspressiooni 
(Schwarze-Zander et al., 2010; Xiang et al., 2004). Seetõttu võib HPgV mõju-
tada ka HIV-i ülekannet ning HIV-iga nakatumist.  
Eestis algas 2000. aastal kontsentreeritud HIV epideemia, kus valdav enamik 
esmasdiagnoosi saajaid olid noored meessoost SN-d. Kuigi viimastel aastatel 
nakatutakse peamiselt sugulisel teel, on enamik HIV positiivsetest siiski SN-d. 
Selline homogeenne populatsioon sobib geneetiliste faktorite ja kaasuvate 
infektsioonide mõju kirjeldamiseks HIV infektsiooni nakatumisele.  
 
UURIMISTÖÖ EESMÄRGID 
Uurimustöö üldine eesmärk oli kirjeldada HIV-ga kaasuvate teiste infektsioo-
nide ning inimese geneetilise faktori mõju HIV-i nakatumisele SN-de seas. 
Uuringu alaeesmärgid olid järgmised: 
1. Teha kindlaks HTLV-1 ja HTLV-2 esinemissagedused ja genotüübid Eesti 
SN-de ja tervete vabatahtlike seas. 
2. Kirjeldada seoseid HTLV-1/2 infektsiooni ja sotsio-demograafiliste fak-
torite, kaasuvate infektsioonide ja narkootikumide süstimisaja pikkuse vahel.  
3. Teha kindlaks inimese pegiviiruse (HPgV) esinemissagedus ja genotüübid 
Eesti SN-de seas ning võrrelda neid vastavate näitajatega tervete vaba-
tahtlike seas.  
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4. Kirjeldada seoseid HPgV ja sotsio-demograafiliste faktorite, kaasuvate 
nakkuste ja süstimisaja vahel.  
5. Kirjeldada seoseid IFNL4 geenis paikneva polümorfismi rs12979860 ja 
HIV-i või HCV-ga nakatumise vahel. 
 
UURITAVAD JA METOODIKA 
Uuringusse kaasati üks SN-de populatsioon ning kontrollgruppidena terved 
vabatahtlikud ning veredoonorid. SN-d kaasati uuritavate juhitud kaasamise 
meetodil (ingl. k. respondent driven sampling ehk RDS) ühest Tallinna süstla-
vahetuspunktist ajaperioodil november kuni detsember 2011. aastal. Kontroll-
grupina kaasati Tartust ajaperioodil september 2011 kuni jaanuar 2012 terved 
vabatahtlikud vanuses 18 kuni 65 eluaastat. Veredoonorite kontrollgrupi puhul 
kaasati 497 veredoonori jääkvered, mis koguti 2010. aastal Tallinna ja Ida-Viru-
maa verekeskustest. Kogu uuring viidi läbi kolmes osas: i) HPgV uuring – 
uuritavateks olid 345 SN-i ning kontrollgrupina kaasati 118 tervet vabataht-
likku; ii) HTLV uuring – uuritavateks olid 345 SN-i ning kontrollgrupina kaasati 
138 tervet vabatahtlikku; iii) IFNL4 rs12979860 uuring – uuritavateks olid 345 
SN-i ning kontrollgrupina kaasati 497 veredoonori jääkvered. 
HPgV uuringus määrati SN-de ja tervete vabatahtlike vereplasmast viiruse 
RNA, mis analüüsiti Giret et al. (2012) kirjeldatud protokolli järgi (Giret et al., 
2011) ning sekveneeriti. Lisaks määrati vereplasmast HPgV E2 valgu vastased 
antikehad, kasutades HGV Ab ELISA kit’i (Atlas Link Technology Co., Ltd, 
Peking, Hiina). HTLV ja IFNλ4 uuringute jaoks eraldati verest inimese 
genoomne DNA (sisaldab ka inimese genoomi integreerunud HTLV proviirust). 
HTLV määrati van Tienen et al (2012) ja Morimoto et al (2007) poolt 
kirjeldatud protokollide järgi (Morimoto et al., 2007; van Tienen et al., 2012). 
Lisaks kaasati kõikidesse PCR-idesse HTLV-1 ja HTLV-2 positiivsed kont-
rollid, mis saadi krooniliselt nakatunud rakuliinidest MT-4 (HTLV-1 positiivne) 
ja Gu (HTLV-2 positiivne). IFNλ4 polümorfism määrati Real-Time PCR Allelic 
Discrimination analüüsi abil.  
Statistilises analüüsis kasutati gruppide võrdlemisel Fisheri täpset testi või 
Mann-Whitney-Wilcoxoni testi. Mudelitest kasutati ühe- ja mitmemõõtmelist 
logistilist regressioonanalüüsi.  
 
PEAMISED TULEMUSED JA ARUTELU 
Kõik terved vabatahtlikud olid HTLV-1 ja HTLV-2 negatiivsed. SN-de seas 
tuvastati ainult üks HLTV-2 positiivne isik, kõik teised olid nii HTLV-1 kui ka 
HTLV-2 negatiivsed. HLTV-1 osas langevad meie tulemused kokku varasemate 
Euroopa riike hõlmanud uuringutega – HTLV-1 esinemissagedus on valdavalt 
väga madal ning kõrgem ainult Rumeenias ja riikides, kus on kõrge HTLV-1 
endeemilistest piirkondadest pärit immigrantide osakaal (Suurbritannia, Prant-
susmaa, Hispaania, Portugal). HTLV-2 esinemissagedus oli kõrge 1990-ndatel 
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aastatel Lõuna- ja Lääne-Euroopa SN-de seas, kuid hilisemates uuringutes on 
näidatud meie tulemustele sarnaselt madalat esinemissagedust (ligikaugu 1%). 
Kolmandikul (33%) SN-del esines HPgV vireemia, kuid HPgV antikehad 
esinesid vaid 2,3% SN-del. HPgV vireemia esinemissagedus oli tervete vaba-
tahtlike seas ligi viis korda madalam (6%), kuid antikehade esinemissagedus 
(1,7%) oli sarnane SN-dega. Sarnaselt varasematele uuringutele oli HPgV 
vireemia esinemine SN-de seas mõjutatud vanusest ja HIV positiivsusest: logis-
tilise regressioonanalüüsi põhjal oli HPgV vireemiaga SN-l ligi kaks korda 
suurem šanss olla HIV positiivne ning HPgV vireemia esinemise šanss vähenes 
vanuse kasvades. Suur HPgV vireemia sagedus SN-de seas võib tuleneda osa-
liselt nende riskikäitumisest – süstalde ja muude süstevahendite jagamine 
soodustab vere teel levivate infektsioonide edasist levikut. Kuid kõrge HPgV 
vireemia SN-de seas võib tuleneda ka HIV-i ja teiste infektsioonide poolt 
tekitatud immuunsüsteemi nõrgestamisest, mille tulemusena ei suudeta HPgV 
infektsioonist vabaneda ning infektsioon muutub krooniliseks. Tõepoolest, 
sarnaselt meie tulemustele on ka varasemates uuringutes leitud, et võrreldes 
HIV negatiivsetega esineb HIV positiivsete seas HPgV vireemiat oluliselt sage-
damini. Madalat HPgV seropositiivsust võivad mõjutada ka HPgV infektsiooni 
iseärasused – vireemiast vabanemise järel ei teki alati HPgV E2 valgu-vastaseid 
antikehasid ning tekkinud antikehad võivad aja jooksul kaduda. Sarnaselt teiste 
Euroopa riike hõlmavate uuringutega oli ka meie uuringus enamik infekt-
sioonidest põhjustatud HPgV genotüüp 2a poolt ning oluliselt vähem esines 
genotüüpi 2b. Teisi HPgV genotüüpe me ei tuvastanud. 
IFNL4 geenis paikneva rs12979860 polümorfismi alleelide ja genotüüpide 
jaotus oli Hardy-Weinbergi tasakaalus ning sarnanesid europiidsesse rassi 
kuuluvate populatsioonide varasemalt kirjeldatud andmetega. Meie tulemused 
ei näidanud statistiliselt olulisi seoseid rs12979860 polümorfismi ja HCV-ga 
nakatumise vahel, kuid see võis tuleneda väga kõrgest HCV seropositiivsusest 
SN-de seas. Samas, meie tulemused näitasid seost antud polümorfismi ja HIV 
positiivsuse vahel. Genotüüpide analüüsist selgus, et rs12979860 TT genotüübi 
kandjatel oli ligi kaks korda suurem šanss olla HIV positiivne, võrreldes mitte-
TT genotüübi kandjatega, seejuures TT genotüübi mõju suurus vähenes süsti-
misaja kasvades. Varasemalt on näidatud, et süstitavate narkootikumide tarvita-
mine ning süstevahendite jagamine, eriti sage süstevahendite jagamine, suu-
rendab vere teel levivate infektsioonide ülekandumise riski. Eeltoodut arvesse 
võttes näitavad meie töö tulemused, et keskkondlikud tegurid (nt süstiv narko-
maania) võivad avaldada suuremat mõju viirusinfektsioonidega nakatumisele 
kui mõned inimese genoomis paiknevad polümorfismid ning pikem riskikäitu-







1.  HTLV-1/2 esinemissagedus Eesti SN-de seas on väga madal. Meie tule-
mused näitavad, et HTLV-1/2 võib küll SN-de populatsioonis olemas olla, 
kuid pole laialt levinud. Seetõttu pole praegu rutiinne testimine HTLV 
infektsioonide suhtes tõenäoliselt kulutõhus.  
2.  Väga madala HTLV-1/2 esinemissageduse tõttu uuritavas populatsioonis 
polnud võimalik hinnata võimalikke seoseid HTLV-1/2 positiivsuse ja sotsio-
demograafiliste faktorite, kaasuvate infektsioonide ja süstimisaja vahel. 
3.  HPgV vireemia esinemissagedus oli tervete vabatahtlike seas madal, kuid 
SN-de seas oluliselt kõrgem, mis näitab, et HPgV levib vere ja vere-
produktide kaudu väga hästi. Madal HPgV seropositiivsus mõlemas populat-
sioonis võib tuleneda HPgV infektsioonile omastest tunnustest – vireemiast 
vabanemisele ei järgne alati HPgV vastaste antikehade tootmine ning anti-
kehad võivad aja jooksul kaduda. Sarnaselt teiste Euroopas läbiviidud uurin-
gutele oli ka meie populatsioonis kõige levinum HPgV genotüüp 2a, teistest 
genotüüpidest tuvastati ainult genotüüp 2b. 
4.  HPgV RNA positiivsed SN-d olid nooremad ja neil oli ligi kaks korda suurem 
šanss olla HIV positiivne, võrreldes HPgV RNA negatiivsete SN-dega. 
HPgV vireemia seos vanusega toetab eelnevalt kirjeldatud nähtust, kus HPgV 
vireemiast vabanemisele ei järgne alati HPgV vastaste antikehade teket. 
HPgV vireemia ei olnud seotud vanusega tervete vabatahtlike hulgas, kuid 
see võis tuleneda madalast HPgV vireemia esinemissagedusest nende seas.  
5.  IFNL4 rs12979860 TT genotüübi kandjad olid võrreldes mitte-TT geno-
tüübiga isikutega suurema tõenäosusega HIV positiivsed, kuid rs12979860 
TT genotüübi mõju HIV-i nakatumisele vähenes süstimisaja kasvades ning 
TT genotüübi efekt oli oluline lühema kui 12 aasta pikkuse süstimisaja korral. 
Seega, IFNL4 rs12979860 TT genotüüp suurendab HIV-iga nakatumise 
riski, aga süstitavate narkootikumide kasutamise mõju on suurem ning pikem 
süstimisaeg vähendab selle geneetilise polümorfismi mõju.  
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